Development of a Fluorescence Quantification

Assay for Mid to High Throughput Drug Screening by Kaul, Pradeep
		
	
	
 
 
	
	
	
Department	of	Cardiovascular	Sciences	
	
	
	
Development of a Fluorescence Quantification 
Assay for Mid to High Throughput Drug 
Screening 
	
	
Pradeep Kaul  
June 2017 
	
	
	
	
	
	
	
Dissertation	submitted	to	the	University	of	Sheffield	for	
degree	of	
Master	of	Philosophy	
	 	
	
		
Acknowledgements	
		First,	I	would	like	to	profoundly	thank	my	supervisor	Dr.	Tim	Chico	for	his		immense	 support.	Not	only	do	 I	 extend	my	gratitude	 for	his	 guidance	but	also	for	putting	up	with	my	rather	erratic	schedule.		I	will	always	be	grateful	for	his	patience.			I	also	want	to	thank	Ms.	Karen	Plant	for	the	help	she	provided	throughout	this	 period.	 	 She	 spent	 a	 lot	 of	 time	 teaching	 me	 various	 laboratory	techniques	 at	 the	 start	 of	 the	 project.	 She	 was	 always	 ready	 to	 help	whenever	asked.		Dr.	 Stephen	 Brown	 from	 RNAi	 facility	 was	 immensely	 helpful.	 He	 helped	with	 image	 acquisition	 and	 analysis.	 	 He	 was	 very	 kind	 to	 spare	 time	 to	explain	functioning	of	the	plate-reader		hardware		and	software.	Prior	work	done	by	Ms.	 Carolyn	Gray	 and	Peter	Novodvorsky	 formed	 the	basis	 of	my	 project.	 	 Mr.	 Aaron	 Savage	 is	 another	 person	 I	 would	 like	 to	mention	for	extending	his	help	whenever	I	needed	it.	I	 would	 like	 to	 thank	 my	 wife	 Stuti,	 who	 apart	 from	 supporting	 me	emotionally	 had	 to	 bail	 me	 out	 financially	 for	 the	 year	 I	 spent	 in	 the	laboratory.	Lastly,	I	would	like	to	acknowledge	my	sons	Prannay	and	Ahaan	who,	many	a	time	were	at	the	receiving	end	of	my	frustrations.			
	 ii				
Abstract			
Background	
	In	 recent	 times	 zebrafish	 (danio	rerio)	 has	 been	 used	 increasingly	 for	 drug	 screening,	target	identification,	pharmacology	and	toxicology.	Quantifying	fluorescence	emitted	by	fluorophores	 is	 a	method	 that	 can	 be	 used	 to	measure	 expression	 of	 a	 gene.	 I	 used	 a	novel	 transgenic	 zebrafish	 line	 to	 develop	 a	 drug	 screening	 assay,	 using	 fluorescence	quantification	 to	 assess	 expression	 of	 	 the	 atheroprotective	 	 	klf2a	 gene,	 to	which	 the	fluorophore	is	tagged.		
Materials	and	Methods	The	 novel	 transgenic	 zebrafish	 line	 (klf2a:GFP;kdrl:RFP)	 was	 developed	 in	 our	laboratory	for	my	experiments.	To	establish	positive	and	negative	controls	for	the	assay,	GFP	fluorescence	patterns,	a	surrogate	for	klf2a	expression	were	observed	in	two	days	post	 fertilization	 (2dpf)	 embryos.	 Images	 were	 acquired	 using	 a	 fluorescence	 stereo-microscope.	Green	fluorescence	was	quantified	using	FIJI	(ImageJ)	software.		GraphPad	Prism	was	used	for	data	analysis.			In	order	to	prevent	flow-dependent	expression	of	klf2a	in	developing	vasculature,	1	cell	stage	 embryos	 were	 injected	 with	 1nl	 of	 0.2mM	 tnnt2	 morpholino	 into	 1	 cell	 stage	embryos.	 No	 blood	 flow	 was	 established	 in	 these	 embryos.	 To	 switch	 off	 the	 flow-	dependent	 expression	 of	 klf2a	 in	 zebrafish	 embryonic	 vasculature	 blood	 flow	 was	interrupted	at	1	day	post	fertilization	stage,	by	treating	embryos	with	anaesthetic	drug,	tricaine.	 To	 further	 examine	 the	 non-flow	 dependent	 klf2a	 expression	 tricaine-only	treated	 embryos	 were	 compared	 with	 embryos	 treated	 with	 tricaine	 and	 lovastatin.	Statins	 like	 lovastatin	 are	 known	 to	 upregulate	 klf2	 through	 non-flow	 dependent	pathways.		
	 iii				
Feasibility	of	using	a	plate-reader	was	established	to	further	develop	the	assay	for	mid	to	high	throughput	drug	screening.	
Results	I	replicated	the	results	to	substantiate	that	klf2a	expression	was	dependent	on	flow	in	the	 vasculature.	 Lovastatin	 treatment	 significantly	 increased	GFP	 fluorescence	 in	2dpf	embryos	as	compared	to	DMSO	(dimethyl	sulphoxide)	treated	embryos.	I	further	showed	that	the	assay	was	reproducible	when	used	for	a	mid-throughput	drug	screening.			 	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 iv				
	
	
Aims	
My	 aim	 was	 to	 develop	 a	 drug	 screening	 assay	 by	 fluorescence	 quantification	 of	reporter	 gene	 GFP	 tagged	 to	 klf2a	 promoter	 in	 a	 double	 transgenic	 zebrafish	 line	
klf2a:GFP;kdrl:RFP.	
	
Hypothesis	
• A	 high	 throughput	 plate-reader	 can	 be	 used	 for	 optimal	 imaging	 and	fluorescence	measurements	of		zebrafish	embryos	in	our	transgenic	line.	
• In	the	double	transgenic	line	used,	GFP	expression	was	flow-dependent.	
• Lovastatin	increased	GFP	fluorescence	in	these	particular	embryos.		
• GFP	 fluorescence	quantification	can	be	used	as	a	whole	organism	 initial	drug-	screening	assay.	
	
Objectives	
The	points	laid	out	in	above	hypothesis	were	tested	as	follows	
• To	assess	the	optimal	way	of	imaging	1	and/or	2dpf	embryos	I	compared	imaging	embryos	 using	 orientation	 tools	 in	 a	 96	 well	 plate	 with	 direct	 pipetting	 of	embryos	into	the	wells	in	a	clear	medium.	
• I	examined	the	effect	of	absent	blood	flow	in	embryos	treated	with	tricaine	and	in	tnnt2	morphants	on	GFP	expression.	
	 v				
• To	see	the	effects	of	Lovastatin	on	GFP	expression	I	performed	a	dose	response	exercise.	
• The	 feasibility	 of	 using	 a	 high	 throughput	 plate-reader	 for	 drug	 screening	was	tested,	first	by	establishing	validity	of	positive	and	negative	controls	and	then	by	using	drugs	from	the	Spectrum	library	for	actual	screening.			
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Chapter	1	
Introduction	
	 		 	 2		
1.1 Krüppel	Like	Factors	(KLFs)	
1.1.1	Krüppel	Like	family	of	transcription	Factors		
	
1.1.1.1	Background			Krüppel	 like	factors	(KLFs)	are	a	 family	of	zinc	 finger	containing	transcription	factors.	These	 factors	 are	 associated	 with	 proliferation,	 differentiation,	 development	 and	apoptosis.	KLFs	 participate	 in	 physiological	 and	 pathophysiological	 functions	 of	many	organ	systems	like	the	cardiovascular,	respiratory,	blood	and	immune	systems.	KLFs	are	also	involved	in	tumor	biology.	(Jiang	et	al.,	2008,	Nandan	and	Yang,	2009).	The	 first	mammalian	krüppel	 like	 factor	was	 found	 in	a	mouse	erythro-leukaemia	 cell	line.	(Miller	and	Bieker,	1993).	
KLFs	 are	 a	 seventeen-member	 family	 of	 transcription	 factors	 that	 form	 a	 part	 of	 the	Sp1/KLF	group	of	transcription	factors	and	share	similar	zinc	finger	structures.	Krüppel	Like	factors	are	aptly	named,	as	they	are	homologous	to	krüppel	(German	for	“cripple”)	protein	 in	Drosophila	melanogaster.	Krüppel	protein	 is	 a	member	of	 the	 “gap”	 class	of	proteins	 and	 its	 expression	 in	 Drosophila	 melanogaster	 embryos	 causes	 altered	abdominal	 and	 thoracic	 segmentation	 resulting	 in	 death.	 (Nusslein-Volhard	 and	Wieschaus,	1980,	Schuh	et	al.,	1986).			
	
1.1.1.2	Conservation	and	Phylogenetic	analysis		Genes	coding	 for	KLF	proteins	are	highly	conserved	 in	mammals.	Krüppel	Like	 factors	also	 have	 homologs	 in	 chicken	 (Gallus	gallus),	 zebrafish	 (Danio	 rerio),	 frogs	 (Xenopus	laevis)	 and	 nematodes	 (Caenorhabtidis	 elegans).	 KLF	 expression	 varies	 in	 different	tissues	(Brey	et	al.,	2009,	Pearson	et	al.,	2008).		
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On	the	basis	of	mode	of	function	KLFs	are	divided	into	three	different	groups.	(Pearson	et	al.	(2008).	
	 		
	
	
KLFs	15	and	17	contain	no	specific	protein	interaction	domain	
	
1.1.1.3	Protein	Structure	of	KLFs.	Zinc	 finger	 domains	 are	 a	 common	 feature	 of	 transcriptional	 factors.	 Several	 features	distinguish	KLFs	 from	other	 zinc	 finger	 transcription	 factors.	The	 carboxy-terminus	of	
KLF	proteins	contains	 three	(Cysteine)2-(Histidine)2	zinc	 fingers.	The	 first	and	second	zinc	 fingers	 contain	25	amino	acids	and	 the	 third	 finger	 contains	23	amino	acids.	The	
Figure	1.1	Phylogenetic	groups	of	Krüpple	like	Factors	(KLFs).		Figure	 showing	 three	 different	 groups	 of	 KLFs.	 Each	 group	 has	 a	characteristic	binding	site	and	acts	either	as	a	translational	repressor	or	a	translational	activator.		CtBP	(Carboxy-terminal	Binding	Protein).	
	 		 	 4		
inter-finger	space	has	a	highly	conserved	7	amino	acid	sequence.		Each	finger	recognizes	three	base	pairs	in	a	DNA	sequence	and	as	such	interact	with	9	base	pairs	
		
	
	
	
	
		
	
	 	
Figure	1.2	Structure	of	KLFs	Schematic	representation	of	three	groups	of	Krüppel	Like	Factors	showing	the	position	of		activator	and	repressor	binding	domains.					
Figure.	1.3	Protein	Structure	of	KLFs.		Schematic	diagram	of	the	structure	of	KLFs	showing	two	C(Cysteine)	and	two	H(Histidine)	residues	in	each	Zn	(Zinc)	finger	and	activation	and	repressor	domains	towards	the	amino-terminal.		
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(Dang	et	al.,	2000).		Zinc	finger	binding	sites	are	similar	among	the	KLFs.	These	include	GC	 rich	 sequences	 like	 5’	CACCC-3’	 or	 the	 GT	 box.	 The	members	 of	KLF	 family	 have	different	 amino-terminal	 regions,	 which	 impart	 functional	 diversity	 to	 them.	 This	variation	 allows	 them	 to	 bind	 different	 co-activators,	 co-repressors	 and	 modifiers.	Histone	acetyl-transferase	binding	site,	Carboxy-terminal	Binding	Protein	(CtBP)	site,		and	Sin3A	binding	site	are	found	in	Krüpple	Like	Factor	groups	1,2	and	3	respectively.	Zinc	finger	domains	also	play	an	important	part	in	nuclear	import	of	KLFs	(Mehta	et	al.,	2009).	Transcriptional	regulation	by	KLFs	 is	mediated	by,	modular	activation	and	repression	domains	in	their	structure.	
KLFs	 undergo	 posttranslational	 modifications	 by	 regulatory	 proteins	 through		processes	 like	 acetylation,	 phosphorylation	 and	ubiquitination	 (McConnell	 and	Yang,	2010).		
	
1.1.2	KLFs	in	organ	development	and	tissue	function	
KLF	 family	 members	 play	 important	 regulatory	 parts	 at	 key	 stages	 of	 organ	development,	their	physiology	and	pathophysiology.	
1.1.2.1	Cardiovascular	development	
KLF2	and	KLF13	play	a	role	in	cardiovascular	development.	KLF13	regulates	cardiac	cell	proliferation	 (Martin	 et	 al.,	 2001).	 KLF2	 is	 an	 important,	 in	 vivo,	 regulator	 of	haemodynamic	 shear	 stress	necessary	 for	normal	 cardiovascular	development	 (Lee	 et	al.,	2006).		
KLF15	is	reduced	in	biopsy	samples	of	patients	with	left	ventricular	hypertrophy	(Fisch	et	al.,	2007).	 Increased	connective	tissue	growth	factor	(CTGF)	expression	and	fibrosis	was	seen	in	 	 	KLF15-/-	mouse	model,	when,	subjected	to	aortic	banding.	KLF15	 inhibits	
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binding	 of	 co-activator	 P/CAF	 thus	 suppressing	 CTGF	 expression,	 which	 in	 turn	decreases	 cardiac	 fibrosis.	 (Wang	 et	 al.,	 2008).	 In	 contrast	KLF5	 promotes	 fibrosis	 in	myocardium	(Shindo	et	al.,	2002).	
KLF10	 prevents	 cardiac	 hypertrophy	 by	 unknown	 mechanisms	 (Rajamannan	 et	 al.,	2007)	
1.1.2.2	KLFs	and	Endothelial	Cells	
KLF2,	4	and	6	are	expressed	in	endothelial	cells	(EC).		
KLF4	 reduces	 adhesion	 of	 inflammatory	 cells	 like	 neutrophils	 and	 platelets	 to	 vessel	endothelium.	 It	 also	prolongs	 clotting	 time	 (Hamik	 et	 al.,	 2007).	KLF6	 induces	 several	genes	 like,	endoglin,	collagen1,	TGFβ	receptor	 type1,	which	are	 important	 for	vascular	remodeling	after	vessel	injury	(Botella	et	al.,	2002).	
KLF2	will	be	discussed	separately	in	subsequent	sections.			
1.1.2.3		Role	of	KLFs	in	other	organ	system	development.		
KLFs	play	roles	in	development	and	maturation	of	respiratory,	hematopoietic,	immune,	gastrointestinal,	skeletal	and	nervous	systems.			
	
1.1.3	Krüppel	Like	Factors	in	Zebrafish	(Danio	rerio)		Zebrafish	 (Danio	 rerio)	 are	 a	 subclass	 of	 teleosts	 that	 have	 arisen	 from	 a	 common	ancestor	 about	 340	 million	 years	 ago.	 This	 ancestor	 seems	 to	 have	 undergone	 an	additional	 round	 of	whole	 genome	 duplication	 also	 known	 as	 teleost	 specific	 genome	duplication	or	TSD.	As	a	result	of	TSD	zebrafish	possesses	26,206	protein	coding	genes,	which	is	more	than	any	other	sequenced	vertebrate	species.	Zebrafish	also	have	a	higher	number	 of	 species	 specific	 genes	 as	 compared	 to	 humans.	 Human	 and	 zebrafish	genomes,	when	directly	compared,	reveal	that	71.4%	of	human	genes	have	at	least	one	zebrafish	 orthologue.	 Reciprocally,	 69%	 of	 zebrafish	 genes	 have	 human	 orthologues.	
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47%	of	human	genes	have	only	one	zebrafish	orthologue.	Many	human	genes	have	more	than	one	orthologue	in	zebrafish	genome,	with	an	average	of	2.28	zebrafish	genes	to	one	human	 gene	 (Vilella	 et	 al.,	 2009).	 The	 Online	 Mendelian	 Inheritance	 in	 Man	 (OMIM)	database	 has	 3176	 human	 gene	 sequences	 that	 bear	 morbidity	 descriptions.	 2601	(82%)	 of	 these	 genes	 have	 a	 zebrafish	 orthologue.	 This	 underlines	 the	 importance	 of	zebrafish	as	a	model	to	study	various	human	diseases	(Howe	et	al.,	2013).		After	 gene	 duplication,	 usually	 one	 gene	 copy	 becomes	 functionally	 silenced	 and	disappears	 overtime.	 This	 process	 is	 called	 non-functionalisation.	Duplicate	 genes	 can	also	 undergo	 neo-functionalization.	 Here	 the	 duplicate	 copies	 develop	 beneficial	mutations	in	one	or	both	copies	that	aid	in	evolution	of	new	functions	over	time.	Gene	duplicates	can	also	undergo	sub-functionalization.	In	this	case	gene	duplicates	together	perform	the	functions	of	a	single	copy	mammalian	orthologue.					Oates	et	al	(Oates	et	al.,	2001)	hybridized	a	fragment	of	the	c-DNA	of	mouse	Klf1	 to	an	adult	 zebrafish	 kidney	 c-DNA,	 Sequence	 analysis	 demonstrated	 presence	 of	 five	independent	 genes,	 each	 containing	 Krüppel	 like	 zinc	 finger	 motifs.	 These	 are	 klf2a,	
klf2b,	klf4,	klf12	and	klfd.			
1.1.3.1	Phylogeny	of	zebrafish	klf	genes		In	an	amino	acid	sequence	comparison	with	other	members	of	KLF	 family	C-	terminals	of	 five	zebrafish	genes	have	 three	 tandem	zinc	 fingers.	The	regions	outside	zinc	 finger	domains	have	diverged	significantly.			Zebrafish	klf2a,	klf2b	and	klf4	proteins	were	similar	 to	mammalian	KLf2	and	KLf4.	The	zebrafish	klf	genes	show	more	similarity	to	each	other	than	to	Klf2	or	Klf4	resulting	in	a	low	 boot-	 strap	 values.	 But	 examination	 of	 amino	 acid	 sequences	 at	 the	 N-termini	 of	
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proteins	 revealed	 five	 highly	 conserved	 blocks	 of	 residues	 separated	 by	 divergent	regions.		The	 syntenic	 relations	 between	 the	 zebrafish	 and	 their	 closest	mammalian	 homologs	support	the	hypothesis	that	klf2a	and	klf2b	are	orthologs	of	Klf2		and	klf4	is	an	ortholog	of	Klf4.	Mammalian	Klf12	and	zebrafish	klf12	are	orthologous.	 	klfd	has	no	mammalian	ortholog.	(Oates	et	al.,	2001)	
1.1.3.2	klf2a	and	klf2b	expression	during	development.		
Klf2a	 and	 klf2b	 genes	 are	 expressed	 during	 gastrula	 stages	 in	 early	 epidermis	 in	 a	partially	 overlapping	 pattern.	 Klf2a	 was	 detected	 in	 ventral,	 animal	 portion	 of	 the	epiblast	 at	 70%	 epiboly	 and	 extended	 vegetally	 as	 epiboly	 progressed.	 Klf2b	 had	 a	similar	 expression	 pattern	 but	 in	 a	 slightly	 wider	 area.	 By	 the	 end	 of	 epiboly	 klf2b	expression	is	lost	in	animal-most	one	third	of	the	epiblast.	Klf2b	had	higher	expression	in	a	lateral	band	extending	around	the	dorsal	midline	of	the	embryo.	Thus	the	domain	of	
klf2a	expression	is	enveloped	by	klf2b.	
Klf2a	expression	was	detected	24hpf	around	the	anus	and	in	small	cluster	of	cells	lateral	to	the	posterior	notochord.	Expression	was	also	noted	in	scattered	cells	in	close	vicinity	of	axial	vessels,	head	vessels	and	heart.	These	expression	patterns	persist	up	to	48	hpf	when	signals	for	klf2a	are	detected	in	the	caudal	fin	and	in	the	pectoral	fins.	
Klf2b	was	 expressed	 in	 the	 superficial	 layer	 of	 the	 epidermis,	 in	 large	 squamous	 cells		present	 dorsally.	 At	 36	 hpf	 this	 expression	 is	markedly	 decreased.	Klf2b	 is	 present	 in	higher	 levels	at	this	stage,	 in	two	cords	of	cells	anterior	and	ventral	to	the	pectoral	 fin	buds.		Zebrafish	klf2a	expression	 is	seen	 in	cells	associated	with	blood	vessels	 in	head,	 trunk	and	 tail,	 but	 not	 in	 intersegmental	 vessels,	 indicating	 that,	 a	 function	 in	 blood	 vessel	development	is	ancestral	for	KLF2	genes	in	vertebrates.	
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klf2b	 expression	 in	 differentiating	 epidermis	 is	 akin	 to	 Klf4	 in	 mouse.	 This	 may	 be	because	 in	mammalian	 lineage	epidermal	expression	was	 lost	 in	KLf2	 and	retained	by	
Klf4.					None	 of	klf2	 genes	were	 seen	 being	 expressed	 in	 developing	 thymus.	 Both	klf2	 genes	were	expressed	in	pectoral	fins	and	may	have	a	role	in	differentiation	of	limb	muscle.		Expression	during	erythrocyte	development,	as	seen	in	zebrafish	and	mammals	suggests	that	function	in	haematopoiesis	is	ancestral.	(Oates	et	al.,	2001)		
1.1.4		Krüpple	Like	Factor	2	(KLF2)	Lingrel	et	al	first	cloned	KLF2	(Anderson	et	al.,	1995).	KLF2	is	a	354	amino	acid	protein,	also	 called	Lung	Krüppel	 like	protein	because	of	 its	 abundant	presence	 in	 lung	 tissue.	Human	KLF2	maps	to	chromosome	19p13.1.	It	has	85%	homology	to	the	mouse	gene.	5’	sequence	 in	 proximal	 promoter	 region	 and	 the	 3’	untranslated	 regions	 are	 conserved	between	 the	 two	 species.	 Though	 the	 sequences	 in	 the	 proximal	 promoter	 show	divergence	between	mouse	and	humans,	a	region	of	75	base-pairs	is	conserved	between	the	two	species.	This	region	functions	as	a	novel	transcriptional	element	important	for	
KLF2	gene	expression	(Wani	et	al.,	1999a).	Structural	domain	mapping	has	identified	an	N	terminal	activation	domain	between	amino	acids	1	and	110	and	an	inhibitory		domain	between	amino	acids	110	and	267.	The	inhibitory	domain	of	KLF2	interacts	with	WWP1,	an	 E3	 ubiquitin	 ligase,	 resulting	 in	 ubiquitination	 and	 proteasome	 mediated		degradation	of	KLF2	(Conkright	et	al.,	2001,	Zhang	et	al.,	2004).	Using	northern	blot	techniques	on	mouse	embryos	at	7,11,15	and	21	days	of	gestation,		
Klf2	expression	 is	evident	 in	mouse	embryos	at	embryonic	day	7	(E7).	The	expression	decreases	by	E11	and	then	increases	around	E15	(Anderson	et	al.,	1995).	
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1.1.4.1	Role	of	KLF2	in	development	Target	deletion	studies	have	shown	that	KLF2	regulates	T-cell	maturation,	normal	lung	development,	 cardiovascular	 development	 and	may	 have	 roles	 in	maturation	 of	 other	systems	like	nervous	systems.	The	following	sections	will	briefly	describe	role	of	klf2	in	development	and	pathophysiology	(McConnell	and	Yang,	2010)	
1.1.4.2.	Role	of	KLF2	in	endothelial	cell	biology	
KLF2	is	the	most	studied	KLF	in	vascular	cell	biology	and	patho-biology.		KLF2	is	highly	expressed	 in	 cultured	 endothelial	 cells	when	 subjected	 to	 prolonged	 shear	 and	 stress	due	to	laminar	flow	(Dekker	et	al.,	2002,	SenBanerjee	et	al.,	2004).	In	vivo	studies	have	shown	that	KLF2	is	expressed	in	the	endothelium	of	human	aortae	in	regions	exposed	to	prolonged	laminar	flow.	KLF2	is	down	regulated	or	absent	in	areas	of	non-laminar	shear	stress	as	is	found	at	the	origin	of	arterial	branches.	These	branch	points	are	more	prone	to	early	atherosclerosis	(Dai	et	al.,	2004).	
1.1.4.3.	Regulation	of	leukocyte	adhesion	to	endothelial	cells	Immune	cells	are	recruited	to	vessel	walls	in	response	to	the	inflammatory	stimulation	of	 the	 endothelial	 cells.	This	 sets	 the	 scene	 for	 a	 series	 of	 complex	 interactions	which	leads	 to	 development	 and	 progression	 of	 atherosclerosis.	 KLF2	 is	 an	 important	transcriptional	regulator	that	counteracts	endothelial	activation.	KLF2	inhibits	cytokine	mediated	induction	of	adhesion	molecules	like	Vascular	Cell	Adhesion	Molecule	(VCAM)-1	and	E-selectin.	This	in	turn	reduces	the	attachment	of	inflammatory	and	immune	cells	to	the	endothelial	cell	lining	of	the	vessel	wall	(SenBanerjee	et	al.,	2004).			
KLF2	 prevents	 endothelial	 cell	 activation	 by	 interleukin	 -1β	 (IL-1β),	 Tumor	 necrosis	factor-	α	 	 (TNF- α),	 Lipopolysaccharide	 (LPS)	 and	 thrombin.	 The	 nuclear	 Factor-	 κB	(NF-κB)	 pathway is	 the	most	 important	 pro-inflammatory	 pathway	 affected	 by	KLF2	action.	 Normally	 in	 the	 absence	 of	 any	 pro-inflammatory	 stimuli	 NF-κB stays	 in	 the	
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cytoplasm	 ,inhibited	 by	 two	 inhibitors,	 IκB	 and	 proteins,	 p100	 and	 p105.	 On	 cellular	stimulation	 these	 inhibitors	 are	 completely	 or	 partially	 broken	 down	 by	phosphorylation.	NF-κB dimers	p50/p65	thus	 formed	move	 into	 the	nucleus	and	alter	gene	 expression.	 	 NF-κB	 activity	 depends	 on	 other	 co	 activator	 proteins	 like	 CREB-binding	 protein	 (CBP),	 Steroid	 receptor-coactivator-1	 (SRC-1),	 IKKα	 and	 p300/CBP	associated	factor	(Arany	et	al.,	1994,	Yamamoto	et	al.,	2003).	
KLF2	 interacts	 with	 CBP/p300,	 a	 key	 co-factor	 for	 NF-κB	 activity.	 KLF2	 reduces	transcriptional	activity	of	NF-κB	by	competing	with	CBP/p300	co-activator	and	 in	 this	process	reducing	expression	of	target	genes	like	VCAM-1	and	E-selectin	 in	response	to	inflammatory	response.	KLF2	also	inhibits	protease	activator	receptor	1	(PAR-1).	This	in	turn	inhibits	thrombin	mediated	induction	of	IL-6,	IL-8	and	monocyte	chemoattractant	protein-1	(MCP-1)	.	Thus	KLF2	 inhibits	endothelial	inflammation	by	inhibiting	multiple	pathways	dependent	on	NF-κB	activity	(Parmar	et	al.,	2006).	
KLf2	 strongly	 inhibits	 Transformation	 Growth	 Factor–β	 signaling	 by	 two	 distinct	mechanisms	involving	SMAD3/4	dependent	transcriptional	activation	and	by	inhibiting	co-factor	activating	protein-1	(AP-1).	Endothelial	cells	overlying	atherosclerotic	plaques	have	 increased	 levels	 of	 nuclear	 activating	 transcription	 factor	 2	 (ATF2).	 KLF2	suppresses	nuclear	translocation	of	ATF2.		(Boon	et	al.,	2007,	Fledderus	et	al.,	2007).		
1.1.4.4	KLF2	and	thrombotic	function	Blood	is	maintained	in	a	fluid	state	by	factors	like	nitric	oxide	(NO),	tissue	plasminogen	activator	(tPA)	and	thrombomodulin	(TM).	Nitric	oxide	(No)	inhibits	platelet	activation	and	 prevents	 platelet	 aggregation.	 Tissue	 plasminogen	 activator	 (tPA)	 converts	plasminogen	 into	 plasmin.	 Plasmin	 causes	 fibrinolysis	 and	 clot	 dissolution	 in	 injured	blood	 vessels	 and	 re-establishing	 blood	 flow.	 Thrombomodulin	 (TM)	 is	 an	 integral	membrane	 protein	 which	 acts	 as	 a	 cofactor	 for	 thrombin.	 This	 interaction	 changes	
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thrombin	 from	 a	 pro-coagulant	 to	 an	 anticoagulant	 factor.	 	 	 KLF	 2	 can	 differentially	regulate	 these	key	 factors.	By	 inducing	TM	expression	KLF2	augments	 antithrombotic	function	 by	 activation	 of	 protein	 C	 to	 activated	 protein	 C	 (APC).	 Furthermore,	 KLF2	overexpression	 inhibits	 procoagulant	 factors	 like	 tissue	 factor	 and	 plasminogen	activator	 inhibitor1	 (PAI1)	 and	 prolongs	 clotting	 time	 under	 flow	 condition.	 KLF2	knockdown	by	small	interfering	RNAs	(siRNAs)	resulted	in	opposite	effect,	establishing	
KLF2	as	a	key	regulator	of	endothelial	gene	expression	in	thrombotic	pathways	(Lin	et	al.,	2005).	
1.1.4.5	KLF2	in	angiogenesis	and	vasculogenesis	Angiogenesis	 is	 important	 in	 physiological	 conditions	 like	 menstruation	 and	 wound	healing	and	also	in	pathological	conditions	like	chronic	inflammation	and	tumors.	KLf2	has	 potent	 antiangiogenic	 effect.	 In	 nude	mice	models	 it	 has	 been	 demonstrated	 that	overexpression	of	KLF2	inhibits	VEGF	mediated	angiogenesis	and	causes	tissue	oedema.	At	 a	 molecular	 level	 KLF2	 at	 least	 partly	 inhibits	 expression	 of	 key	 VEGF	 receptor	VEGFR2	 by	 competing	 with	 SP1	 for	 binding	 to	 VEGF	 promoter	 (Bhattacharya	 et	 al.,	2005).	Semaphorin-3F	factor	known	to	inhibit	tumor	cell	migration	is	potently	induced	by	 KLF2	 (Dekker	 et	 al.,	 2006).	 	 KLF2	 by	 reducing	 endothelial	 cell	 migration	 and	proliferation	inhibits	angiogenesis.		The	above	observations	are	contrary	to	the	ones	made	in	zebrafish	by	Nicoli	et	al.	They	found	that	klf2a	in	presence	of	flow	induces	microRNA126.	miRNA	126	inhibits	spred1,	a	 negative	 regulator	 for	 VEGF	 expression	 thus	 promoting	 angiogenesis	 (Nicoli	 et	 al.,	2010).	The	link	between	KLF2	and	microRNA126	induced	VEGF	upregulation	has	been	seen	in	duodenal	vessels	of	human	cirrhotic	patients	(Kobus	et	al.,	2012)		Homozygous	deletion	of	Klf2	 causes	normal	vascular	patterning	but	defective	vascular	morphology.	There	 is	deficient	migration	of	 vascular	 smooth	muscle	 cells	 (VSMC)	and	
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pericytes	to	vascular	tubes	resulting	in	defective	tunica	media	that	is	not	compact.	These	mice	 die	 around	 E12-E14	 (Kuo	 et	 al.,	 1997).	 In	 Xenopus	 KLF2	 knockdown	 causes	inhibition	in	Flk1	expression	and	results	in	gross	abnormalities	in	vascular	development	(Meadows	et	al.,	2009).	
KLF2	 inhibits	hypoxia	 inducible	actor	(HIF)-1α.	KLF2	knockdown	increased	expression	of	 HIF-1α	 and	 its	 target	 genes,	 IL-8,	 angiopioetin-a	 and	 vascular	 growth	 factor.	Furthermore,	KLF2	inhibited	hypoxia	induced	vascular	tube	formation	(Kawanami	et	al.,	2009)	
Klf2	 -/-	 and	 Klf4-/-	 double	 knockout	 	mice	 show	 defects	 in	 vascular	 integrity	 and	 die	around	day	E10.5.	The	cross	sectional	structure	of	 the	vessels	show	disruptions	of	 the	endothelial	 cell	 layer.	 On	 a	 molecular	 level	 there	 is	 decreased	 expression	 of	 eNOS	(endothelial	 nitric	 oxide),	 VEGFR2	 and	 occludin,	 a	 tight	 junction	 protein.	 Interacting	with	 other	 KLFs,	 KLF2	 plays	 a	 role	 in	 developing	 and	 maintaining	 vascular	 integrity	(Chiplunkar	et	al.,	2013).			
1.1.4.6	KLF2	in	regulating	vascular	tone	Under	physiological	conditions	vasodilatory	factors	like	C-natriuretic	peptide	and	eNOS	are	 induced	 by	 laminar	 flow	 and	 help	 to	 regulate	 vascular	 tone.	 In	 pathological	conditions	 expression	 of	 endothelin-1	 (ET-1),	 a	 potent	 vasoconstrictor	 is	 increased.	 A	single	KLF2	binding	site	is	critical	for	the	activation	of	eNOS	promoter.	This	activation	is	brought	 about	 by	 KLF2	 which	 recruits	 co-activator	 CBP/p300	 complex	 to	 eNOS	promoter.	 KLF2	 can	 also	 inhibit	 expression	 of	 endothelin,	 adrenomedulin	 and	angiotensin	 converting	 enzyme,	 three	 important	 genes	 regulating	 vascular	 tone.	(SenBanerjee	et	al.,	2004,	Dekker	et	al.,	2005).	
KLF2	 decreases	 the	 expression	 of	 caveolin1,	which	 encodes	 a	 cell	membrane	 protein.	Caveolin1	is	a	negative	regulator	of	eNOS	in	endothelial	cells	(Razani	et	al.,	2001).	
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Mouse	 embryos	 lacking	KLF2	 die	 around	 day	 E14	 of	 heart	 failure	 due	 to	 high	 output	state,	due	to	lack	of	vascular	tone.	These	physiological	abnormalities	are	also	observed	in	 zebrafish	 embryos	 after	 morpholino	 knockdown	 of	 klf2a	 (Lee	 et	 al.,	 2006).	 This	supports	 the	 fact	 that	 shear	and	stress	 causes	 changes	 in	KLF2	 expression	 in	vascular	endothelium,	which	 in	 turn	 regulates	 vascular	 tone	 	 to	maintain	 normal	 physiological	haemodynamics.		
	 	
	
	
	
	
	
1.1.4.7		Role	of	KLF2	in	Lung	development.	
KLF2	is	highly	expressed	in	lung	tissue.		KLF2	deficient	mice	die	in	utero	between	days		E14.	Hence,	it	is	difficult	to	study	the	Role	of	KLF2	in	lung	development.			But,	lung	bud	tissue	cultures,	from	KLF2-/-	mice	at	age	E11.5	grow	normal	tracheobronchial	tree.		
Figure	1.4	KLF2	in	vascular	homeostasis		Figure	representing	mechanisms	that	are	involved	in	various	processes	controlled	by	KLF2	in	maintaining	vascular	and	endothelial	homeostatsis.	Abbreviations:	VEGFR2	(Vascular	endothelial	growth	factor	receptor-2),	SEMA3F	(Semaphorin-3F),	VCAM-1	(Vascular	cell	adhesion	molecule-1),	eNOS	(endothelial	nitric	oxide	synthetase),	CNP	(C-type	natriuretic	peptide),		ASS		(arginosuccinate	synthetase),	PAI-1	(plasminogen	activator	inhibitor-1),	TM	(thrombomodulin),	tPA	(tissue	plasminogen	activator).		
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When	chimeric	mice	were	created	by	injecting	KLF2-/-	embryonic	stem	(ES)	cells	into	the	blastocysts	of	wild	type	mice	all	organs	except	lung	is	developed	normally.	Animals		that	developed	 high	 chimerism	 died	 at	 birth	 with	 lungs	 that	 did	 not	 develop	 beyond	 late		canalicular	phase.	(Wani	et	al.,	1999b)		1.1.4.8		Role	of	KLF2	in	erythropoiesis	
Klf2-/-	 mice	 die	 during	 embryonic	 development	 between	 day	 E12.5	 to	 E14.5.	 These	embryos	show	 intra-embryonic	haemorrhage,	anemia	and	growth	retardation.	 	Klf2	 -/-	embryos	have	significantly	 increased	number	of	primitive	erythroid	cells	 that	undergo	apoptotic	death	(Basu	et	al.,	2005).	KLF2	and	KLF1	might	have	redundant	 functions	 in	regulating	 embryonic	 genes	 like	 β	 globin,	 primitive	 erythropoiesis	 and	 endothelial	development.	
1.1.4.9	KLF2	in	Immune	system	regulation.	Kuo	 et	 al	 ((Kuo	 et	 al.,	 1997)	 found	 that	KLF2	 (LKLF)	 was	 needed	 to	 	maintain	 single	positive	T-Lymphocytes	in	a	quiescent	state	for	their	viability	in	peripheral	organs	and	blood.	Klf2	 is	 essential	 for	T	 cell	 trafficking.	KLf2	 deficient	 thymocytes	 show	 impaired	expression	 of	 receptors	 like	 	 Sphingosine	 1	 phoshate	 	 (S1P1),	 CD62L	 and	 β7	 integrin	which	are	responsible	for	thymocyte	migration	and	peripheral	trafficking	(Carlson	et	al.,	2006).	KLF2	 has	 been	 identified	 as	 a	 key	 transcriptional	 factor	 that	 prevents	 naive	 T	cells	 from	 expressing	 inflammatory	 chemokine	 receptors	 necessary	 for	 acquiring	migratory	patterns	of	active	T	lymphocytes	(Sebzda	et	al.,	2008).	
	1.1.4.10	KLF2	in	metabolic	regulation	
Klf2	and	KLF3	inhibit	adipocyte	differentiation.	In	a	3T3-L1	model,	levels	of	KLFs	2	and	3	are	 high	 in	 undifferentiated	 preadipocytes	 and	 not	 in	 mature	 adipocytes.	 KLF2	 is	 a	down-regulator	 of	 adipogenesis.	 KLF2	 directly	 suppresses	 peroxisome	 proliferator-
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activated	 receptor	 gamma	 (PPARγ)	 expression,	 and	 prevents	 differentiation	 of	preadepocyte	into	mature	adipocytes	(Banerjee	et	al.,2003).		
	
1.1.5	Mechanisms	regulating	KLF2	
1.1.5.1	Sensing	of	shear	and	stress	by	endothelial	cells	Several	 theories	have	been	put	 forward	to	explain	how	various	shear	stress	 forces	are	sensed	by	endothelium.	The	theories	proposed	are,	a) Ion	channel	activation	b) Caveolae	mediated	regulation	of	Calcium	c) G-protein	coupled	receptor	activation	d) Tyrosine	kinase	receptor	activation	e) Adhesive	protein	activation	f) Glycocalyx	elongation	and	g) 	Bending	of	primary	cilia			The	 physico-chemical	mechanisms	 involved	 in	 this	 endothelial	mechano-transduction	are	 incompletely	 understood.	 Current	 best	 evidence	 supports	 role	 of	 membrane	cytoskeleton	and	membrane	fluidity	in	shear-stress	sensing	by	endothelium.		((Johnson	et	al.,	2011)		1.1.5.2	Flow	mediated	regulation	of	KLF2			Kumar	and	colleagues	provided	the	first	insights	into	the	mechanisms	involved	in	KLF2	expression.	 They	 identified	 a	 single	 consensus	myocyte	 enhancing	 factor	 2	 (MEF2)	 –binding	site	in	conserved	region	of	the	KLF2	promoter.	MEF2	is	a	member	of	MADS	box	(MCM1,	 Agamous,	 Deficiens,	 Serum	 response	 factor)	 family	 of	 transcription	 factors.	MADS	box	factors	bind	to	A/T	rich	sequences.	(Kumar	et	al.,	2005).	
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MEF2A	and	MEF2C	are	implicated	as	critical	regulators	of	endothelial	biology.		MEF2A	is	associated	with	coronary	artery	disease	and	MEF2C	plays	a	role	in	endothelial	integrity	and	 permeability	 (Hayashi	 et	 al.,	 2004,	 Wang	 et	 al.,	 2003).	 MEF2	 null	 mice	 express	similar	 phenotype	 to	 Klf2	 null	 mice	 and	 die	 in	 early	 embryonic	 age.	 This	 could	 be	explained	by	the	fact	that	KLf2	and	MEF2	are	part	of	the	same	transcriptional	axis	(Bi	et	al.,	 1999).	Berk	et	 al,	have	previously	 shown	 that	 extracellular-signal	 regulated	kinase	(ERK5)	 is	 a	 highly	 flow	 induced	 factor	 thus	 linking	MEF	 factors	 and	KLF2	 regulation	(Yan	et	al.,	1999).		Using	 DNA	 affinity	 chromatography	 techniques,	 PCAF	 (p300/CBP-associated	 factor),	heterogeneous	 nuclear	 ribonucleoprotein	 D	 and	 nucleolin	 have	 been	 identified	 as	proteins	that	bind	to	KLF2	promoter.	These	proteins	bind	the	proximal	KLF2	promoter	as	part	of	phosphoinositide-3kinase	(PI3K)	dependent	shear	stress	regulating	complex	(Huddleson	et	al.,	2004).	Parmar	and	colleagues	showed	that	flow	responsive	rise	in	KLF2	expression	is	mediated	via	 MEK5/ERK5/MEF2	 transcriptional	 pathway	 (Parmar	 et	 al.,	 2006).	 Laminar	 flow	through	shear	stress	induces	phosphorylation	of	ERK5	and	MEF2,	which	is	necessary	for	
KLF2	expression.	These	mechano-transduction	events	are	suppressed	by	blocking	AMPK	(AMP-activated	protein	kinase)	underlining	the	role	of	AMPK	as	part	of	 the	MEK5	and	ERK5	pathway.			Laminar	shear	stress	results	in	uncoupling	of	HDAC5	(Histone	deacetylase	5)	and	MEF2	resulting	in	increase	transcriptional	activity	of	MEF2	and	upregulation	of	KLF2	and	enos	(Wang	et	al.,	2010).		Thioredoxin	 inhibitory	 protein	 (TXNIP)	 suppresses	 KLF2	 expression	 and	 promotes	monocyte	adhesion	to	endothelial	cells	(Wang	et	al.,	2012).		
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MicroRNAs	 are	 18-24	 base	 pair	 RNA	 fragments	 which	 are	 involved	 in	 post-	transcriptional	regulation	of	gene	expression.	Dicer,	an	important	enzyme	in	microRNA	synthesis,	knockdown	increased	level	of	KLF2	in	human	umbilical	vein	endothelial	cells		(HUVECs).	 			.											 						
Figure:	1.5	Pathways	involved	in	upregulation	of	KLF2.	Schematic	representation	of	different	pathways	involved	in	upregulation	of	
KLF2.	Pathways	on	the	left	show	processes	involved	in	flow	dependent	upregulation.	Right	side	of	the	figure	shows	how	statins	upregulate	KFL2	in	a	non-flow	dependent	manner	through	Rho	pathway.	PI3K	(Phosphoinositde-3-kinase),	MEK	(mitogen-activated	protein	kinase),	ERK	(extracellular	signal	regulated	kinase	5),	PCAF	(p300/CBP	associated	factor),		hnRNP	(heterogeneous	nuclear	riobonucleoprotein),	MEF2	(myocyte	enhancer	factor	2),	Rho	(Ras	homologue	gene	family	member	A,	KLF2	(Krüppel	like	factor	2)	
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This	suggests	that	microRNAS	play	a	role	 in	KLF2	regulation.	Laminar	flow	suppresses	mirna92a	 and	 increases	KLF2	 expression	 as	 shown	 by	 Bonaeur	 et	 al	 (Bonauer	 et	 al.,	2009,	Fang	and	Davies,	2012).		
					Activin	receptor-like	kinase5	(Alk5)	activation	by	shear	stress	in	cardiovascular	system	causes	 ERK5	 activation,	 by	 phosphorylation	 and	 subsequent	 induction	 of	 KLF2	expression.	Klf2	 in	turn	activates	Smad	7	and	forms	a	negative	feedback	loop	to	inhibit	TGF-β	cascade	activation	(Egorova	et	al.,	2011).	p21	activated	kinase1	(PAK1)	is	a	flow	and	 statin	 responsive	 target	 of	 MEK5/ERK5	 pathways.	 KLF2	 suppresses	 PAK1	
Figure	1.6	Pathways	involved	in	downregulating	KLF2	expression.	Schematic	representation	of	pathway	responsible	for	the	downregultion	of	
KLF2.	TNFα	(tumor	necrosis	factor	α),	IL1β	(Interleukin	1β),	P65	(nuclear	factor-κB	p65),	HDAC	4/5	(histone	deacetylase	4/5),	MEF2	(myocyte	enhancer	factor	2)		
KLF2	(krüppel	like	factor	2)			
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expression	 and	 prevents	 ERK5	dependent	 endothelial	 cell	migration,	which	 is	 seen	 in	pathological	angiogenesis	and	plaque	rupture	in	atherosclerotic	lesions.	(Komaravolu	et	al.,	2015)		
1.1.5.3	Non	flow	dependent	regulation	of	KLF2	Proinflammatory	 stimuli	 to	 endothelial	 cells	 inhibit	KLF2	 expression.	 Inhibiting	KLF2	results	in	allowing	these	inflammatory	processes	to	carry	on	in	an	unimpeded	manner.	Kumar	 et	 al	 reported	 that,	 TNF-α	 through	 NFκB	 and	 histone	 deacetylase	 pathways	reduced	KLF2	expression.	NFκB	inhibitor	IκB	abolished	this	effect.	Treatment	of	HUVECs	with	 trichostatin	 A,	 which	 inhibits	 histone	 decetylase	 resulted	 in	 no	 effect	 on	 KLF2	expression	by	TNF-α.	Histone	deacetylase	4	and	5	and	p	65,	a	component	of	NFκB,	form	a	 trimolecular	complex	with	MEF2	 factors	on	KLF2	promoter	and	 inhibit	 the	ability	of	MEF2	 to	 induce	 KLF2	 expression	 (Kumar	 et	 al.,	 2005).	 Endothelial	 activation	 by		inflammatory	cytokines	causes	KLF2	suppression	and	uninhibited	activity	of	deleterious	NFκB	pathways.		Apart	from	lowering	cholesterol,	class	of	drugs	called	statins,	exert	an	atheroprotective	effect	by	de	novo	upregulation	of	KLF2.	The	up-regulatory	effects	of	statins	on	KLF2	are	due	 to	 inhibition	 of	 3-hydroxy-3-methylglutaryl	 coenzyme	 A	 (HMG	 CoA).	 The	 statin	mediated	effect	on	HUVECs	(Human	Umbilical	Vein	Endothelial	Cells)	was	abrogated	by	adding	 mevalonate	 to	 statin	 treated	 HUVEC	 cultures.	 Isoprenoids,	 geranylgeranyl	pyrophosphate	(GGPP)	and	farsenyl	pyrophosphate	(FPP)	are	down-stream	products	of	mevalonate	pathway.	These	 isoprenoids	help	 in	tethering	 important	signaling	proteins	like	Ras	and	Rho	 to	 cell	membranes	and	 regulating	 their	 activity.	To	 further	elucidate	the	down	stream	pathways,	HUVECS	were	 treated	with	geranylgeranyl	pyrophosphate	(GGPP)	 and	 farsenyl	 pyrophosphate	 (FPP).	 GGPP	 treated	 HUVECs	 showed	 complete	reversal	 of	 statin	 mediated	 KLF2	 induction	 and	 FPP	 treated	 cells	 showed	 a	 modest	
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reduction	in	KLF2	expression.	Geranyl	transferase	(GGT)	and	Farsenyl	transferase	(FT)	are	 the	 enzymes	 that	 covalently	 bind	 these	 isoprenoids	 to	 proteins	Rho	 and	Ras.	 The	HUVECs	cultures	were	treated	with	the	inhibitors	of	these	transferases.	GGTI	treated	cell	cultures	 showed	KLF2	 upregulation	 that	was	 comparable	with	 statin	 treated	 cells.	 FTI	treated	 cells	 were	 not	 able	 to	 reproduce	 this	 upregulation	 of	 KLF2	 at	 similar	concentrations	of	 the	 inhibitor.	This	 confirms	 that	GGPP	associated	Rho	pathways	are	mediators	of	statin	induced	KLF2	induction	(Parmar	et	al.,	2005).		MEF2	binding	site	of	
KLF2	promoter	is	necessary	for	KLF2	upregulation	by	statins	(Sen-Banerjee	et	al.,	2005)			 								
	
		
				
Figure	1.7	Cytokine-mediated	down	regulation	of		KLF2.	TNFα	(tumor	necrosis	factor	alpha),	IL1β	(interleukin1β),		P300	(E1A	binding	protein	300),	P50	(nuclear	factor	κB	transcription	factor	50),	VCAM	(vascular	adhesion	molecule),	KLF2	(Krüppel	like	factor2),		
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	Resveratrol	 is	 a	 stilbenoid	 (a	 type	 of	 naturally	 occurring	 plant	 phenol).	 It	 activates	Sirtulin1	 (SIRT1),	 a	 nicotinamide	 adenine	 dinucleotide	 (NAD)	 dependent	 deacetylase,	which,	 in	 turn	 induces	 KLF2	 upregulation.	 KLF2	 upregulation	 occurs	 via	 a	 MAPK	 5	(mitogen	activated	protein	kinase	5)/MEF2	pathway.	
	
	
	
	
	
Figure	1.8:	Mevalonate	pathway	and	KLF2	expression.		Figure	shows	steps	in	mevalonate	pathway	and	site	of	action	of	statins	and	farnesyl	and	geranyl	transferase	inhibitors.	HMG	Co	enzyme	A:	(3-hydroxyl-3-methylglutaryl	coenzyme	A),	Isopentanyl	PP	(isopentanyl	pyrophosphate),	FPP	(Farnesyl	Pyrophosphate);		GGPP	(Geranylgeranyl	Pyrophosate);	GTI	(	Geranyl	transferase	inhibitor);	FTI	(Farnesyl	Transferase	inhibitor),	KLF2	(krüppel	like	factor2)			 	
	 		 	 23		
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Figure	1.9	Upregulatory	functions	of	KLF2	Induction	of	vasoprotective	substances	as	induced	by	KLF2.		APC	(activated	protein	C),	P300	(E1A	binding	protein	300),	TM	(thrombomodulin),	KLF2	(kruppel	like	factor2),		eNOS	(endothelial	nitric	oxide),	NO	(nitric	oxide).	
2
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1.1.6	KLF2	and	Atherosclerosis.	Atherosclerosis	 is	 the	 most	 common	 pathology	 of	 large	 and	 medium	 size	 vessel		resulting	 in	vital	organ	 ischaemic	damage.	 “Lipid	 insudation”	and	“fibrin	encrustation”	are	 old	 hypotheses	 put	 forward	 to	 explain	 pathogenesis	 of	 atherosclerosis.	 	 Recent	hypotheses	 have	 qualified	 vascular	 endothelium	as	 a	 “dynamically	mutable	 interface”,	responsible	 for	 reacting	 to	 a	 variety	 of	 local	 and	 systemic	 stimuli.	 Manifestations	 of	endothelial	 dysfunction	 include	 glycoprotein	 permeability	 and	 oxidation,	 enhanced	mononuclear	leucocyte	adhesion	and	intimal	accumulation,	altered	extra	cellular	matrix	metabolism	and	dysregulation	of		haemostatic-	thrombotic	balance.		Pathophysiological	stimuli	for	arterial	endothelial	dysfunction	relevant	to	atherogenesis	are	 pro-inflammatory	 cytokines,	 bacterial	 products,	 viruses,	 advanced	 glycation	 end	products,	 hypercholesterolaemia	 and	 oxidized	 lipo-proteins,	 that	 accumulate	 in	 the	vessel	wall	(Gimbrone	and	Garcia-Cardena,	2013).	It	 has	 been	 observed	 for	 a	 long	 time	 now	 that	 the	 earliest	 lesions	 of	 atherosclerosis	develop	in	a	distinct	non-random	pattern,	in	areas	of	arterial	tree	that	are	subjected	to	changes	 in	 flow	patterns,	 as	near	branch	points.	This	observation	has	 led	 scientists	 to	explore	 links	 between	 atherosclerosis	 and	 blood	 flow	 patterns	 (Cornhill	 and	 Roach,	1976).		Laminar	 shear-	 stress	 as	 found	 in	 unbranched	 tubular	 arteries	 that	 carry	 uniform	laminar	 flow	 are	 typically	 protected	 from	 early	 atherosclerosis.	 Presence	 of	 various	endothelial	mechano-transducers	and	down-stream	signaling	pathways	 link	externally	applied	 mechanical	 stimuli	 to	 intracellular	 and	 intranuclear	 events	 that	 bring	 about	complex	 system	 of	 biomechanical	 endothelial	 gene	 regulation	 (Davies	 et	 al.,	 2013,	Davies,	1995).			
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Dai	 et	 al	 analysed	 flow	 patterns	 using	 three-dimensional	 (3D)	 fluid	 dynamic	 analysis.	They	 characterized	 an	 “atheroprone”	 pattern	 in	 carotid	 sinus	 region	 and	“atheroprotective”	pattern	in	distal	internal	carotid	artery.	Human	cultured	endothelial	cells	were	subjected	to	these	two	flow	patterns.	Exposure	to	atheroprone	flow	induced	dysregulation	of	expression	and	organization	of	cytoskeletal	and	junctional	proteins	and	activated	deleterious	NFκB	pathways.	The	 gene	 that	was	most	differentially	 regulated	between	 two	 flow	 patterns	 was	 KLF2	 (Dai	 et	 al.,	 2004).	 The	 focal	 nature	 of	atherosclerosis	 in	 human	 arteries	 and	 its	 long	 established	 correlation	 between	particular	 haemodynamic	 environment	 might	 be	 explained	 by	 the	 spatial	 patterns	 of	
KLF2	expression.	The	 following	 evidence	 further	 makes	 a	 case	 for	 links	 between	KLF2	 expression	 and	atherosclerosis.	ApoE	null	mice	bearing	a	hemizygous	deficiency	of	Klf2	exhibited	a	31-37%	increase	 in	atherosclerotic	 lesion	area	as	compared	to	 littermate	controls	(Atkins	et	 al.,	 2008).	 Myeloid	 cell-specific	 KLF2	 inactivation	 leads	 to	 an	 increase	 in	atherosclerosis	 in	LDLR-/-	murine	model	 (Lingrel	et	 al.,	2012).	KLF2	 suppression	 in	T	cells	 and	monocytes	 leads	 to	 a	 proinflammatory	 phenotype	 in	 these	 cells	 (Das	 et	 al.,	2006).	Atheroprotective	 flow	 upregulates	 certain	 antioxidant	 genes	 and	 strongly	 activates,	transcription	factor,	nuclear	factor	erythroid–2–related–factor-2	(Nrf2).	KLF2	and	Nrf2	act	synergistically	to	activate	the	expression	of	a	substantial	fraction	of	flow-dependent	atheroprotective	genes	(Fledderus	et	al.,	2008).	
KLF2	 and	 Nrf2	 at	 present	 seem	 to	 be	 two	 “critical	 regulatory	 nodes”	 in	 vascular	homeostasis	 and	 may	 be	 relevant	 targets	 for	 pharmacological	 agents	 (Rader	 and	Daugherty,	2008).	
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There	 is	 experimental	 evidence	 that	 KLF2	 expression	 triggers	 production	 of	extracellular	vesicles	containing	microRNAs.	These	exert	a	paracrine	effect	on	adjacent	vessel	 wall	 components	 and	 reduce	 atherosclerosis	 in	 murine	 ApoE-/-	 model	(Hergenreider	et	al.,	2012).			
1.2	Zebrafish	in	drug	screening	
	
1.2.1	Zebrafish	as	a	model	for	cardiovascular	research	In	the	last	decade	zebrafish	has	been	increasingly	used	in	investigating	human	diseases	and	biological	processes.	Zebrafish	(Danio	rerio),	originally	natives	of	the	tropical		southeast	 Asian	 rivers,	 are	 available	 throughout	 the	 world.	 Apart	 from	 following	 the	trend	 of	 using	 least	 sentient	 organisms	 in	 science,	 zebrafish	 provide	 certain	 scientific	advantages.	These	are:	a) Genetic	similarity	to	humans	Zebrafish	 are	 vertebrates,	 hence	 share	 a	 high	 degree	 of	 sequence	 and	 functional	homology	with	humans.	b) Easier	to	house	and	care	Due	to	their	small	size	and	relatively	simple	living	environment	it	is	easier	to	house	and	raise	zebrafish.			c) Easy	to	see	Zebrafish	 embryos	 are	 transparent,	 hence	 impact	 of	 any	 genetic	 manipulation	 or	drug	effect	is	easy	to	see	and	capture	with	various	imaging	modalities.	d) Fecundity	
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Zebrafish	 lay	 upto	 300	 eggs	 per	 week,	 as	 such	 are	 capable	 of	 large	 number	 of	offsprings	 as	 compared	 to	 rodents.	Embryos	 are	 externally	 fertilized	by	males	 and	grow	very	quickly.				e) Easier	to	induce	genetic	changes	Genetic	 changes	 can	 be	 brought	 about	 by	 injecting	 embryos	 at	 1	 cell	 stage	 with	relevant	genetic	constructs	or	by	simply	adding	mutagen	to	the	medium.	f) does	not	need	circulation	during	embryonic	development	In	the	 initial	days	of	development	2-4mm	zebrafish	embryos	are	not	dependent	on	circulation	 for	 growth.	 Embryos	 continue	 to	 grow	 as	 they	 gain	 sufficient	 oxygen	through	diffusion.		Zebrafish	screens	are	typically	carried	out	in	live	fish	embryos	or	larvae	exhibiting	fully	integrated	vertebrate	organ	system	and	exhibiting	diverse	biological	processes.	These	advantages	make	 zebrafish	 a	 very	 attractive	model	 for	 cardiovascular	 research.	Cardiovascular	 development	 can	 be	 imaged	 whilst	 it	 is	 happening	 in	 wild	 type	 or	transgenic	 zebrafish	 using	 fluorescent	 reporters.	 Zebrafish	 do	 not	 spontaneously	develop	 cardiovascular	 diseases	 analogous	 to	 those	 seen	 in	 humans.	 However	mechanisms	 postulated	 to	 play	 a	 role	 in	 human	 disease	 can	 be	modeled	 and	 studied.	Successful	 zebrafish	models	 have	 been	 described	 to	 study	 thrombosis,	 arteriogenesis,	inflammation,	cardiomyopathy	and	cardiac	regeneration	(Chico	et	al.,	2008).			
1.2.2	Chemical	screening	in	zebrafish	Traditional	 methods	 of	 small	 molecule	 discovery	 involved	 trial	 and	 error	 testing	 of	chemical	compounds	on	phenotypic	outcomes	in	animals	and	in	cell	cultures.	But	in	past	decades	emphasis	has	been	 laid	on	 “target	driven	approaches”,	which	 seek	 to	 identify	novel	 therapeutics	 based	 on	 prior	 knowledge	 about	 the	 single	 biological	 target.	 This	technique	has	delivered	far	fewer	first	in	class	drugs	(Swinney	and	Anthony,	2011).		
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Phenotype-driven	approaches	seem	to	have	done	better	for	following	probable	reasons.			1. Phenotype-driven	 approaches	 can	 identify	disease	modifying	drugs	 even	 in	 the	absence	 of	 a	 validated	 target.	 For	 example,	 ezetimibe	 was	 discovered	 for	 its	cholesterol	lowering	effects	years	before	its	target	Niemann-Pick	C1-like	protein	1	(NPC1L1).			2. Most	efficacious	drugs	may	benefit	from	activity	at	multiple	targets	and	thus	be	a	“magic	shotgun	rather	than	a	magic	bullet”	for	a	polygenetic	disorder	(Roth	et	al.,	2004).	3. Small	 molecules	 derived	 from	 phenotypic	 screens	 often	 have	 been	 further	selected	 for	 positive	 pharmacological	 properties	 such	 as	 low	 toxicity,	 ability	 to	make	it	to	the	appropriate	target	site	and	also	have	the	ability	to	avoid	or	exploit	endogenous	enzymes	or	transporters.		4. Whole	organ	phenotypic	screening	holds	further	advantages,	as	this	approach	is	target	 agnostic	 and	 holistic.	 Such	 screens	 not	 only	 include	 targets	 relevant	 to	disease	but	also	to	chemical	activation,	transport,	toxicity	and	other	side	effects.	They	 also	offer	 screening	 and	 counter	 screening	 in	 the	 same	assay	 resulting	 in	discovering	compounds	with	desirable	effects	and	passing	out	compounds	with	undesirable	qualities.		5. As	 a	 consequence,	 compounds	 advancing	 from	phenotypic	 screens	 are	 often	 of	higher	quality	than	hits	from	in	vitro	target	based	screens.	Live	zebrafish	were	used	for	the	first	time	for	drug	screening	in	a	96	well	plate,	 in	the	year	2000,	by	adding	small	amounts	of	compound	to	fish	water.	Small	molecules	found	this	 way	 are	 helpful	 in	 understanding	 vertebrate	 development	 and	 identifying	 novel	genes	involved	(Peterson	et	al.,	2000).		
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There	are	hundreds	of	examples	of	small	molecules	that	have	conserved	effects	in	both	humans	 and	 zebrafish.	 It	 is,	 therefore,	 reasonable	 to	 assume	 that	 many	 bioactive	compounds	identified	in	zebrafish	screens	will	maintain	their	activity	in	humans.				There	is	now	a	strong	evidence	about	mechanisms	that	regulate	drug	distribution	across	physiological	 barriers	 like	 blood	 brain	 barrier	 and	 tissue-specific	 transporters	 in	zebrafish	 (Fleming	 et	 al.,	 2013)	 (Popovic	 et	 al.,	 2014).	 Small	 molecule	 testing	 in	zebrafish	 not	 only	 replicated	 the	 effects	 of	 individual	 human	 drugs	 but,	 drug	 –	 drug	interactions	were	also	mimicked.	This	would	suggest	that	drug	distribution,	metabolism	and	excretion	studies	are	also	possible	in	zebrafish	(Chng	et	al.,	2012).		Though	zebrafish	possess	a	full	complement	of	cytochrome	P450	(CYP)	genes,	genome	duplication	and	functional	redundancy	have	hampered	a	thorough	study	of	conservation	of	metabolism	 of	 small	molecules	 in	 zebrafish.	 In	 spite	 of	 the	 reasonable	 evidence	 of	functional	parallels,	extrapolation	must	be	carried	out	carefully	as	drug	metabolism	may	vary	 at	 different	 stages	 of	 development	 and	 a	 part	 of	 a	 particular	 pathway	 may	 not	reflect	the	whole	pathway.		
1.2.3	Successes	so	far			66	drug	screens	have	been	reported	in	zebrafish	so	far.	These	screens	have	had	diverse	phenotypic	 targets	 ranging	 from	embryo	morphology	 to	 cardiac	physiology	and	 sleep.	Some	have	shown	new	effects	of	existing	drugs	whereas	others	have	discovered	novel	compound	classes.	Therapeutic	potential	of	Prohema,	a	stabilized	version	of	prostaglandin	E2	(PGE2)	was	first	 discovered	 in	 zebrafish.	 In	 situ	 hybridization	 in	 embryos	 showed	 that	 Prohema	boosts	number	of	haemopioetic	stem	cells	(HSCs).	After	phase	II	clinical	trials,	it	is	used	for	 pre-treatment	 ex	 vivo	 conditioning	 of	 umbilical	 cord	 blood	 in	 patients	 receiving	
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heamopoietic	stem	cell	transplant	for	leukaemia	or	lymphoma	(Lord	et	al.,	2007,	Cutler	et	al.,	2013).	Other	compounds	that	were	discovered	are:	Dorsomorphin,	 a	 pyrizolopyrimidine,	 inhibits	 bone	 morphogenetic	 protein	 (BMP)	receptor,	 which	 is	 an	 activin	 receptor	 like	 kinase	 2	 	 (ALK2)	 in	 humans	 and	 Alk8	 in	zebrafish.	Dorsomorphin	and	its	derivatives	 like	LDN-193189	are	being	tested	to	treat	fibro-osseous	 dysplasia	 and	 anaemia	 of	 inflammation	 (Yu	 et	 al.,	 2008).	Dorsomorphin	was	discovered	in	a	zebrafish	drug	screen	seeking	molecules	that	affected	normal	body	organization	during	embryogenesis.	Proto-1	 and	 its	 derivatives	 are	 benzothiophene	 carboxamides	 which	 are	 being	investigated	 to	 prevent	 effect	 of	 aminoglycoside	 antibiotics	 which	 kill	 hair	 cells	 in	internal	ear	and	cause	hearing	loss	(Owens	et	al.,	2008).	Again	the	otoprotective	effect	of	Proto-1	was	discovered	in	a	10,960	compound	screen	in	zebrafish.	Both	these	compounds	have	been	approved	for	preclinical	studies.		Transgenic	and	mutant	zebrafish	screens	have	unveiled	new	effects	that	a	drug	already	in	 use	 can	 have.	 AML1-ETO	 is	 a	 transgenic	 zebrafish	 model	 incorporating	 leukemia	oncogene	 AML1-ETO.	 Cyclooxigenase	 inhibitors	 were	 found	 to	 suppress	luekaemogenesis	in	these	fish.	WNT-β-	catenin	pathway	was	implicated	in	self	renewal	of	 leukaemia	 stem	 cells.	 This	 has	 been	 confirmed	 in	 murine	 models.	 As	 the	cyclooxygenase	 inhibitors	 are	 already	 approved	 for	 safe	 human	 use,	 Phase	 1	 clinical	studies	to	confirm	these	effects	will	be	replicated	in	humans	were	easily	set	up.	(Klimek	et	al.,	2012).		Another	 such	example	 is	promise	 shown	by	glucocorticoids	 in	 treating	 long	QT	 (LQT)	syndrome.	Zebrafish	model	for	long	QT	syndrome	was	created	by	kcnh2	gene	mutation.		Drug	 screening	 of	 existing	 drugs	 identified	 fluandrenolide	 as	 a	 potent	 suppressor	 of		
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LQT	 like	 phenotype.	 Clinical	 trials	 started	 subsequently	 show	 a	 probable	 role	 for	dexamethasone	in	LQT	syndrome	(Peal	et	al.,	2011).		
1.2.4	Screens	for	mechanism	of	action			Discovering	 mechanism	 of	 action	 of	 small	 molecules	 discovered	 in	 zebrafish	 drug	screens	 remains	one	of	 the	most	 substantial	hurdles.	Phenotype-based	drug	 screens,	many	a	times	throw	up	unexpected	and	transformative	new	insights	into	disease	under	investigation.	 Computational,	 biochemical	 and	 genetic	 techniques	 can	 be	 used	 to	discover	 mechanism	 of	 action.	 All	 these	 techniques	 can	 be	 applied	 to	 the	 zebrafish	small	molecule	screens.			Affinity	 chromatography	 and	 mass	 spectroscopy	 techniques	 have	 identified	 protein	phosphatase2A	 (PP2A)	 and	 mitochondrial	 malate	 dehydrogenase	 as	 targets	 for	perphenazine	and	visnagin	for	their	actions	in	T-Cell	acute	lymphoblastic	leukemia	(	T-Cell	 ALL).	 and	 doxorubicin	 induced	 cardiomyopathy	 respectively	 (Gutierrez	 et	 al.,	2014,	Asimaki	et	al.,	2014).				One	of	the	most	effective	tools	in	zebrafish	screening	is	a	large	collection	of	phenotypes	associated	 with	 specific	 gene	 mutations	 and	 knockdowns.	 Identifying	 similarity	between	 drug	 effect,	 induced	 phenotype	 and	 genetic	 phenotype,	 can	 provide	 clues	towards	principal	drug	target.	Dorsomorphin	phenocopies	loss	of	fin	mutant	indicating	a	BMP	pathway	for	 its	effect.	Similarly	Kalihinol-F	causes	several	effects	on	zebrafish	embryos	 like	 undulation	 of	 notochord,	 defective	 neural	 development	 and	haematopoiesis,	 which	 mimics	 calamity	 mutants	 with	 disrupted	 function	 of	 Copper	transporting	 ATPase,	 atp7a.	 This	 led	 to	 hypothesis	 that	 kalihinol	 F	 chelates	 copper.	This	was	biochemically	proven	as	exogenous	copper	rescued	the	mutation	(Sandoval	et	al.,	 2013).	 Another	 example	 of	 multi-dimensional	 phenotype	 matching	 and	 pheno-
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clustering	 is	Fumagillin	an	antiangiogenic	 compound	known	 for	more	 than	60	years.	Zebrafish	 embryos	 treated	 with	 Fumagillin	 showed	 phenotypes	 similar	 to	 WNT5	mutants	that	have	cranio-facial	and	skeletal	developmental	abnormalities	(Zhang	et	al.,	2006).		The	number	and	variety	of	phenotypes	that	can	be	distinguished	in	a	whole	organism	greatly	exceeds	the	number	distinguishable	in	cultured	cells.	Phenotype	matching	can	be	a	powerful	way	of	determining	mechanism	of	action	of	small	molecules.		
	
1.2.5	Use	in	Toxicology	screens	Zebrafish	as	opposed	to	mammalian	models	can	be	deployed	very	early	in	a	toxicology	screen.	Zebrafish	toxicology	screens	that	are	run	parallel,	can	help	in	eliminating	toxic	compounds	 at	 a	 very	 early	 stage	 and	prioritize	 “hits”	 for	 further	 development.	 	 This	approach	will	help	toxic	compounds	“failing	fast”.	Zebrafish	 have	 been	 shown	 to	 replicate	 mammalians	 models	 for	 cardiotoxicity,	hepatotoxicity,	 nephrotoxicity	 and	 reproductive	 toxicity	 (Ducharme	 et	 al.,	 2015,	Driessen	et	al.,	2015).				 		
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Aims	
My	 aim	 was	 to	 develop	 a	 drug	 screening	 assay	 by	 fluorescence	 quantification	 of	reporter	 gene	 GFP	 tagged	 to	 klf2a	 promoter	 in	 a	 double	 transgenic	 zebrafish	 line	
klf2a:GFP;kdrl:RFP.	
	
Hypothesis	
• A	 high	 throughput	 plate-reader	 can	 be	 used	 for	 optimal	 imaging	 and	fluorescence	measurements	of		zebrafish	embryos	in	our	transgenic	line.	
• In	the	double	transgenic	line	used,	GFP	expression	was	flow-dependent.	
• Lovastatin	increased	GFP	fluorescence	in	these	particular	embryos.		
• GFP	 fluorescence	 quantification	 can	 be	 used	 as	 a	whole	 organism	 initial	 drug	screening	assay.	
	
Objectives	
The	points	laid	out	in	above	hypothesis	were	tested	as	follows	
• To	assess	the	optimal	way	of	imaging	1	and/or	2dpf	embryos	I	compared	imaging	embryos	 using	 orientation	 tools	 in	 a	 96	 well	 plate	 with	 direct	 pipetting	 of	embryos	into	the	wells	in	a	clear	medium.	
• I	examined	the	effect	of	absent	blood	flow	in	embryos	treated	with	tricaine	and	in	tnnt2	morphants	on	GFP	expression.	
• To	see	the	effects	of	Lovastatin	on	GFP	expression	I	performed	a	dose	response	exercise.	
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• The	 feasibility	 of	 using	 a	 high	 throughput	 plate-reader	 for	 drug	 screening	was	tested,	first	by	establishing	validity	of	positive	and	negative	controls	and	then	by	using	drugs	from	the	Spectrum	library	for	actual	screening.			
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2.1	Zebrafish	Husbandry	
2.1.1.	Background	Zebrafish	(Danio	rerio)	is	a	teleost	fish	of	Cyprinid	family	in	the	class	Actinopterygii	(ray-finned	 fish).	 The	 lineages	 leading	 to	 cyprinids	 and	 mammals	 split	 about	 450	 million	years	ago.	Zebrafish	genome	is	1.7	gigabases	in	size	and	is	divided	into	25	chromosomes.	Zebrafish	genome	is	about	half	the	size	of	human	genome	and		has	been	completely	cloned.	There	are	 two	homologues	of	 the	mammalian	equivalent.	Gene	duplication	accounts	 for	only	20%	of	zebrafish	genes	identified.	This	suggests	that	functioning	of	the	ancestral	genes	in	 teleosts	 may	 be	 shared	 by	 two	 different	 genes.	 Each	 of	 these	 genes	 have	 a	 more	restricted	 function	 than	 the	 original	 gene.	 This	 can	 help	 in	 studying	 gene	 function	 in	zebrafish	as	the	function	of	each	gene	will	be	less	complex.		Streisinger	first	used	zebrafish	to	study	vertebrate	development	in	1981.	Soon	after	that	zebrafish	embryology	was	studied	and	using	genetic	manipulation	methods	 thousands	of	mutant	lines	were	characterized.	There	are	several	hundred	laboratories	in	the	world	where	zebrafish	models	are	used	to	unravel	various	gene	functions.	Sanger	center	in	the	UK	alongwith	groups	in	Tubingen	(Germany)	and	Utrecht	(Netherlands)	have	completed	sequencing	whole	zebrafish	genome.		
2.1.2	Characteristics	of	Zebrafish	as	an	experimental	model	The	zebrafish	embryo	has	 the	 following	characteristics	 that	make	 it	 ideal	 for	 studying	embryonic	 development.	 Fertilization	 of	 eggs	 and	 further	 development	 are	 external.	Embryos	 are	 relatively	 large	 and	 transparent,	 which	 allows	 direct	 visualization	 of	organogenesis.	Development	is	rapid	and	in	two	days	all	features	of	vertebrate	body	can	be	 seen.	Most	 of	 organ	 systems	 are	 smaller	 and	 less	 complex	 versions	 of	mammalian	
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organs	needing	 far	 fewer	 cells	 in	an	organ	 to	perform	requisite	 function.	For	example	zebrafish	kidney	consists	of	a	single	glomerulus	and	bilateral	ducts	that	run	throughout	the	 trunk.	 Also	 zebrafish	 larvae	 are	 able	 to	 swim	 and	 search	 for	 food	 in	 5	 days	 post-fertilization.	 A	 number	 of	 unique	 features	 in	 zebrafish	 facilitate	 genetic	 analysis,	inbreeding	 schemes	 and	 stock-keeping.	 The	 advantages	 score	 over	 the	 fact	 that	generation	time	of	2-4	months	is	not	small.	(Streisinger	et	al.,	1981)		
	2.1.3	Zebrafish	Handling		Our	 institution	 has	 a	 state	 of	 art	 zebrafish	 aquarium.	 All	 animal	 work	 was	 done	 by	following	home	office	regulations.	I	always	worked	with	Ms.	Karen	Plant,	who	held	the	requisite	license.		The	water	 temperature	 and	 room	 temperature	 is	maintained	 between	 25-27	 degrees	Celsius.	 Zebrafish	 are	 kept	 on	 a	 fourteen-hour	 light	 and	 10	 hour	 dark	 cycle	 using	appropriate	 timers.	 The	 water	 supply	 to	 the	 aquarium	 is	 maintained	 by	 recycling	 it	through	 a	 big	 common	 filter.	 From	 the	 filter,	water	 is	 pumped	 up	 to	 a	 reservoir	 kept	above	the	racks	of	aquaria	 in	the	fish	room.	From	the	reservoir	water	is	distributed	to	the	aquarium	by	gravity	flow.	Flow	rate	can	be	adjusted	for	each	row.	An	exchange	rate	of	 about	 three	 volume	 changes	 per	 hour	 is	 recommended.	Water	 is	 kept	 in	 constant	motion	 and	 debris	 is	 removed	 automatically.	 	 All	 the	 fish	 are	 kept	 in	 serial	 tanks	 or	overflow	containers.	Fish	are	fed	twice	a	day	on	the	weekdays	and	once	a	day	over	the	weekends.	Laboratory	Squeeze	bottles	 are	used	 to	 squirt	 the	 food	 into	 the	 tanks.	Fish	are	usually	fed	dry	food	flakes	and	live	brine	shrimps	(Artemia	nauplia).				
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2.1.4 Transgenic	lines	used	Nacre	 Wild	 type	 zebrafish	 which	 are	 depleted	 of	 any	 melanin	 were	 used	 for	 out-crossing.	Double	transgenic	line,	klf2a:GFP;kdrl:RFP,	used	was	engineered	by	Ms.	Caroline	Gray	in	our	 laboratory.	 BAC	 transgenesis	 was	 used	 to	 generate	 a	 construct	 driving	 GFP	expression	under	control	of	the	native	zebrafish	klf2a	promoter	with	Tol2	transposase	flanking	 sequences.	 This	 was	 injected	 into	 1cell	 stage	 zebrafish	 embryos	 that	 were	raised	to	adulthood.	F0	founders	identified	by	PCR	and	subsequent	outcrossing		isolated	a	 single	 transgenic	 line	 klf2a:GFP.	 The	 single	 transgenic	 line	 thus	 produced	 was	 out-crossed	 with	 kdrl:RFP	 transgenics	 expressing	 RFP	 in	 endothelial	 cells.	 The	 double	transgenics	thus	founded,	were	raised	to	adulthood.		
Figure	2.1:	Assembly	of	tanks	in	aquarium		Image	showing	assembly	of	breeding	tanks	in	the	aquarium	with	continuous	water	supply	at	the	top	and	flows	to	the	lower	racks		
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2.2 Collecting	zebrafish	embryos	
2.2.1	Marbling		Marbling	tanks	have	an	inner	plastic	tank	in	which	bottom	is	replaced	by	a	fine	wire	grid	having	 a	 pore	 size	 of	 roughly	 2mms.	 A	 few	 glass	 marbles	 are	 placed	 in	 the	 tank.	Zebrafish	 are	 very	 aggressive	 and	 the	marbles	 provide	 hiding	 places	 for	 the	 fish.	 The	inner	 tank	 is	 placed	 in	 an	 outer	 plastic	 tank.	 There	 is	 about	 2	 cm	 space	 between	 the	mesh	and	bottom	of	the	outer	tank.	The	tops	of	the	two	tanks	are	flush	so	that	the	fish	do	not	 fall	 in	between	 the	 two	 tanks	 and	eat	 the	 eggs.	This	 assembly	 is	 lowered	 into	 the	large	 serial	 tanks	 the	 previous	 evening	 (Day	 -1).	 Embryos	 are	 collected	 the	 following	morning	after	the	lights	are	switched	on	and	20	to	30	minutes	of	undisturbed	mating	are	allowed.		
2.2.2	Pairmating	The	embryos	I	used	were	mostly	obtained	by	pair-mating	technique.		
2.2.2.1	Materials	
• Pair–mating	tanks	Pair-mating	 tanks	 have	 an	 inner	 acrylic,	 mating	 sleeve	 with	 multiple	 holes	 in	 the	bottom.	The	mating	sleeves	also	have	a	groove	 in	 the	middle	 to	house	a	separator.	The	mating	sleeve	is	housed	in	a	one	litre	plastic	tank.	Both	the	containers	are	level	at	the	top	so	that	the	fish	do	not	escape	into	the	outer	box.	This	design	helps	the	eggs	to	sink	to	the	bottom	of	the	outer	tank	and	prevent	the	adults	from	eating	the	eggs.					
• Plastic	Tea-strainer	A	plastic	tea	strainer	was	used	to	strain	embryos	from	the	pair-mating	tanks.	
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• Petri	dish:	90mm	petri	dish	was		used	for	collecting	the	embryos.		
• Squeeze	bottles	Squeeze	bottles	containing	fish	water	were	used	to	gently	wash	embryos	into	90mm	petri	dish.					
2.2.2.2	Method.		Male	and	female	zebrafish	were	identified.	Usually,	one	female	and	one	male	was	placed	in	 the	 two	 compartments	 created	by	 the	 separator	 in	 the	 pair-mating	 tanks.	 12	 to	 16	such	pairs	were	set	up.		 	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure.	2.2	Pair-mating	assembly.		Pair-mating	assembly	showing,	an	inner	plastic	sleeve	with	a	separator	and	a	lid	housed	in	a	1	litre	plastic	tank.	The	bottom	of	the	plastic	tank	is	fenestrated.	These	fenestrations	let	the	eggs	through	to	the	outer	tank	and	prevent	adult	fish	from	eating	the	eggs.		
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2.3	Embryo	medium				E3	 was	 used	 as	 a	 medium	 in	 which	 embryos	 were	 incubated	 for	 up	 to	 5	 days	 post-fertilization.	Embryos	were	euthanized	by	putting	them	into	household	bleach.		E3	medium	was	made	from	a	10X	stock	solution.		1X	E3	medium	contains	the	following	reagents:	Sodium	Chloride	(NaCl)		 	 5mM	Potassium	Chloride	(KCl)		 	 0.17	mM,		Calcium	Chloride	(CaCl2)	 	 0.33mM	Magnesium	Sulphate	MgSO4		 0.33mM	Methylene	blue	 3	drops	in	1000mls			
2.4 Injecting		zebrafish	embryos.	Following	materials	and	methods	were	used	for	micro-injection	of	zebrafish	embryos.		
	
2.4.1	Embryos		Embryos	 were	 collected	 and	 screened	 for	 1-2	 cell	 stage	 under	 a	 stereo-microscope	(Leica)	with	 a	 long	working	 distance.	 These	 embryos	were	 injected	with	 troponin	 T2	(tnnt2)	and	standard	control	morpholinos.		
2.4.2	Microinjection	apparatus	
• Stereomicroscope	with	a	long	working	distance	
• Pneumatic	injector,	Picopump	PV	820	(Precision	Instruments)		
• 1mm	glass	capillary	tubes	(TW100F-4	by	World	Precision	Instruments).	
• Micro-pippette	needle	puller	(Sutter	Instruments	P-97).	
• P10	pipette			
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• Number	5	Dupont	Microforceps	(	World	Precision	Instruments)			
• Graticule	(PYSER-	SGI)	
• Immersion	oil.	
• Microscope	slide	
• Plastic	pipette	
2.4.3 Morpholinos	Morpholinos	are	 synthetic	nucleic	acid	analogs	approximately	25	base	pairs	 long.	 In	a	morpholino	 standard	 nucleic	 acid	 bases	 are	 attached	 to	 a	methylene-morpholine	 ring	linked	 through	 phosphorodiamidate	 groups.	 	 Morpholinos	 act	 by	 binding	 to	 a	 target	sequence	within	a	RNA,	preventing	other	molecules	that	might	otherwise	interact	with	the	sequence	for	successful	translation.	Morpholinos	also	function	by	modifying					
	
	
	
					pre-mRNA	 splicing	 by	 preventing	 small	 nuclear	 ribonucleoproteins	 (snRNP)	 from	binding	 to	 their	 targets	 at	 the	 borders	 of	 the	 introns	 on	 a	 pre-mRNA	 strand.		(Summerton	and	Weller,	1997)	
	
Figure	2.3	Structure	of	Morpholinos.	The	above	figure	compares	A. Basic	structure	of	DNA		B. 	Morpholino	containing	a	hexa-carbon	morpholine	ring	and	phosphodiamidate	bonds.					
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2.4.4	Methods	
2.4.4.1	Preparing	Morpholinos	for	injection	As	shown	in	the	table	below	standard	control	and	troponint2	(tnnt2)	were	used	in	my	project.		Morpholinos	were	sourced	from	Gene	Tools.			
MO	
Name		
Sequence	(5’-3’)	 Amount	
injected	
function	
Standard		
Control	
MO	
CCTCTTACCTCAGTTACAA	 1nl	
(0.2mM)	
none	
Tnnt2	MO	 CATGTTTGCTCTGATCTGACACGCA	 1nl	
(0.2mM)	
Translation	
block	 				Morpholinos	 were	 diluted	 to	 a	 stock	 concentration	 of	 1mM	 and	 stored	 at	 room	temperature.	0.2mM	solution	of	morpholinos	was	prepared	as	follows:		4	µls	of	1mM	stock	 solution	of	Morpholinos	was	pipetted	out	 into	 an	eppendorf	 tube	containing	10	µls	of	milliQ	water	and	6µl	of	1in10	phenol	red	(1%).	The	solution	thus	prepared	was	placed	 first	 on	 a	 vortex	 and	 then	 in	 a	 centrifuge	 (Genfuge)	 and	 spun	at	10000	 rpm	 for	 30	 seconds.	 The	 eppendorf	 (EPPENDORF)	 tube	 was	 then	 placed	 in	 a	warm	bath	at	650C	 for	5	minutes	 to	make	sure	 there	was	no	aggregation.	 	The	0.2mM	solution	thus	prepared	was	stored	at	room	temperature	and	used	for	injecting	embryos.		
	
	
Table	1:	Structure	of	morpholinos	used.	Molecular	structure	of		standard	control	and	Tnnt2	morpholinos	used	in	experiments.	
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2.4.4.2	Preparing	microinjection	needles	1mm	 outer	 diameter	 glass	 capillary	 tubes	 were	 placed	 in	 a	 needle	 puller	 (Sutter	instruments	 P-97).	 Micropippette	 puller	 was	 programmed	 to	 following	 settings	 heat	350,	 pull	 60	 and	 velocity	 80.	 	 The	 needles	 thus	 produced	 were	 stored	 in	 a	 90	 mm	petridish	(STERILIN)	on	a	rolled	paper	tape	with	sticky	side	up.		
2.4.4.3	Embryo	Collection	Once	the	 lights	were	turned	on	in	the	morning	separators	were	removed	from	the	5-6	pair-mating	 tanks	 and	 20	 -30	 minutes	 of	 undisturbed	 mating	 time	 was	 allowed.	Embryos	were	collected	using	a	plastic	sieve.	These	were	washed	into	a	petridish	using	aquarium	water	in	a	squeeze	bottle.		After	quick	screening,	under	microscope	one	cell	stage	embryos	were	 lined	up	against	one	side	of	a	glass	slide	placed	in	an	inverted	petridish	lid.	The	embryos	were	lined	up	in	a	single	file	using	a	plastic	pipette	and	a	seeker.	Excess	water	was	removed	by	pressing	down	on	the	glass	slide	and	sucking	water	by	a	plastic	pipette.	
2.4.4.4	Microinjection	of	embryos	2-3	µls	of	0.2mM	tnnt2	Morpholinos	was	pipetted	into	the	microinjection	needles	using	a	 micropipette	 tip.	 The	 needles	 were	 shaken	 a	 few	 times	 to	 make	 sure	 that	 the	morpholinos	were	loaded	into	the	tip	without	any	air	bubbles.		The	 loaded	needle	was	mounted	onto	a	picopump.	The	tip	of	the	needle	was	carefully	snipped	 off	 under	 a	microscope	 using	 number	 5	micro-forceps.	 Pneumatic	 pump	was	activated	using	a	foot	pedal.		A	 drop	 of	 immersion	 oil	was	 placed	 on	 the	micrometer	 (graticule	 PYSER-SGI).	 It	was	subsequently	placed	under	the	microscope.	 	The	volume	of	 injection	was	calibrated	by	adjusting	 air	 pressure	 and	 the	 injection	 time.	 The	 drop	 of	 morpholino	 spanning	 one	millimeter	on	the	micrometer	gave	an	injecting	volume	of		500	picolitres.		
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1	 nanolitre	 (nl)	 of	 0.2mM	 Tnnt2	 morpholino	 was	 injected	 into	 the	 yolk	 sac	 area	 of	embryos	already	lined	up	against	a	microscope	slide.		The	 process	 was	 repeated	 to	 inject	 another	 batch	 of	 embryos	 with	 1nl	 of	 0.2mM	standard	control	morpholino.	Once	injected	embryos	were	plated,	labeled	and	incubated	at	280	C.		Morpholinos	(MO)	used	in	the	experiment	were	standard	control	morpholino	and	Tnnt2	morpholino		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	2.4.	Injecting	1-cell	stage	embryos.	A. Showing	arrangement	of	embryos	lined	up	against	a	glass	slide	B. Shows	calibrating	the	micro-injector	to	inject	a	volume	of	500	picolitres	per	injection.	C. An	embryo	injected	with	morpholino.	Phenol	red	added	to	the	morpholino	solution	acts	as	an	indicator	to	confirm	the	injection.			
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2.5	Screening	for	double	transgenics:	
	
2.5.1	Materials		
• Fluorescent	microscope	(Zeiss,	Axio	Zoom	V16)	
• Seeker	
• Plastic	pipette	(STARLAB	Ltd)	
• Petri	dish	(STERILIN)	
• E3	medium		
2.5.2	Method	All	embryos	collected	were	plated	onto	petridishes	with	50	embryos	in	each	petridish.	After	incubating	overnight,	injected	and	uninjected	embryos	were	screened.	Only	double	transgenics	,	i.e,	red	and	green	fluorescence	positive,	embryos	were	identified	and	used	in	subsequent	experiment		All	 embryos	 were	 observed	 under	 fluorescence	 stereomicroscope	 (Zeiss,	 Axio	 Zoom	V16)	 at	 50X	 to	 70X	 magnification.	 Embryos	 that	 were	 red	 and	 green	 fluorescence	positive	were	 selected	 for	 rest	 of	 the	 experiments.	 A	 seeker	was	 used	 to	 bunch	 these	embryos	 to	 one	 side	 of	 the	 petridish	 and	 plastic	 pipette	was	 used	 to	 aspirate	 out	 the	embryos	into	petridishes	containing	fresh	E3	without	methylene	blue.	
	
2.6	Dechorionation	
2.6.1.Materials		
• Long	focal	distance	stereomicroscope	(Leica	S6E,	Leica	Microsystems)	
• Seeker	
• No	5	Dupont	micro-forceps	(World	Precision	Insruments)	X2	
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2.6.2	Method	Embryos	were	placed	under	 the	microscope	 in	a	petridish.	Each	embryo	was	steadied	with	one	pair	of	microforceps	and	the	chorion	was	entered	carefully	with	the	tips	of	the	other	microforceps,	thus	releasing	the	embryos.			 	
	
	
	
	
2.7	Preparing	agarose	molds	for	acquiring	images		
2.7.1	Materials.	
• Black-walled	clear	bottom	96	well	plate	(Greiner)	
• 	3-D	printed	mold	(3-D	printed	in	RNAi	lab,	University	of	Sheffield)		
• Flat	reagent	dish	(Oxford	Lab	Equipment)	
• Micropipette	(P200,	Sutter	Instruments	P-97)		
2.7.2	Method			Wittbodt	 described	 the	 method	 to	 create	 agarose	 molds	 for	 uniform	 and	 correct	orientation	 of	 zebrafish	 embryos	 for	 imaging	 (Wittbrodt	 et	 al.,	 2014).	 Steps	 of	 the	process	I	followed	are	as	follows,	
Figure	2.5	Dechorionation	Image	showing	the	process	of	dechorionation	of	1dpf	embryos	with	two	pairs	of	micro-forceps.	Released	embryos	are	seen	in	the	same	field.	
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1. Previously	 prepared	 1%	 LMP	 agarose	 (Sigma-	 Aldrich)	 was	 heated	 in	 a	microwave	till	it	became	liquid.		2. It	was	allowed	to	cool	and	then	poured	it	into	a	flat	reagent	dish	and	allowed	to	cool.		3. 50µls	of	 liquid	agarose	was	added	to	each	well	 in	one	column	of	a	black	walled	clear	bottom,	96	well	plate	(Greiner)	4. Agarose	was	allowed	to	cool	off	in	the	wells	for	30	seconds	to	1minute.		5. The	 3-D	 printed	mold	was	 gently	 lowered	 into	 the	 column	 of	wells	 containing	agarose.		6. The	mold	was	removed	after	after	30	minutes.		7. The	 tip	 of	 a	 P200	 pipette	 was	 cut	 for	 facilitating,	 atraumatic,	 aspiration	 of	zebrafish	embryos.		8. Each	embryo	was	aspirated	in	200µls	of	clear	E3	medium	and	placed	in	the	well		9. Zebrafish	embryos	were	prodded	into	these	molds	using	a	microinjecting		needle	under	a	brightfield	microscope.		
	 					
	Figure	2.6.		Zebrafish	embryo	
orientation	tools.	Top	figure:	3-D	printed	orientation	tool.	Bottom	figure:	Schematic	cross	sectional-image	of	a	96	plate	well	showing	a	zebrafish	within	the	agarose	mold	created	by	the	orientation	tool	for	optimal	imaging.		(Westhoff	et	al.,	2013)		
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2.8	Preparing	different	treatments.	
2.8.1	Lovastatin	Materials	required	
• Lovastatin	(Sigma-Aldrich,	CAS	#75330-75-5)	
• Analytical	balance	(Oxford	Lab	Equipment)	
• DMSO	(Sigma-Aldrich	#	67-68-5)	
• Micropipettes	(World	Precision	Instruments)	
• Falcon	tubes	(50	milliliters)	(Oxford	Lab	Equipment)			
• 10	millimeter	glass	pipette	
• Electric	pipette	aspirator	(Isolab)		Lovastatin	(Sigma-	Aldrich)	was	purchased.	One	gram	of	Lovastatin	was	weighed	using	an	 analytical	 balance.	 50	milliliters	 (ml)	 of	DMSO	 (dimethyl	 sulphoxide)	was	 pipetted	out	 using	 an	 electric	 pipette	 puller	 into	 a	 50ml	 falcon	 tube.	 Lovastatin	 was	 added	 to	DMSO	to	give	a	concentration	of	50mM	(millimolar).	The	solution	was	placed	on	a	vortex	to	 ensure	 complete	mixing	 of	 lovastatin.	 This	 50mM	 stock	 solution	 was	 stored	 in	 10	microliters	(µl),	50µls	and	2	ml	aliquots	in	appropriate	sized	eppendorf	tubes.	The	tubes	were	covered	in	a	silver	foil	and	stored	at	-80o	C.		To	 prepare	 Lovastatin	 4µM	 for	 treatment,	 50mM	 stock	 solution	was	 thawed	 at	 room	temperature.	3.2µL	of	50mM	lovastatin	was	diluted	in	300µL	of	DMSO.		This	was	added	to	40mls	of	clear	E3	solution	in	a	falcon	tube.	This	gave	a	final	Lovastatin	concentration	of	4µM.	
2.8.2	Tricaine				1. Tricaine	(MS222,	Sigma)	stock	solution	(4mg/ml)	2. E3	medium	
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3. 10	ml	glass	Pipette	4. 50	ml	Falcon	tubes	(Oxford	Lab	Equipment)	5. Electric	pipette	aspirator	(Isolab)	33.4	mls	 of	 clear	 E3	 solution	was	 pipetted	 out	 using	 a	 10ml	 pipette	with	 an	 electric	puller.	6.6	mls	of	 	stock	solution	of	 tricaine	was	added	to	give	a	 final	concentration	of	0.66mg/ml.		
2.8.3	Lovastatin	+	Tricaine	33.4	mls	of	E3	were	pipetted	out	into	a	falcon	tube.	6.6	mls	of	tricaine	stock	solution			(4mg/ml)	were	 added	 to	 E3	medium.	 3.2	 µl	 of	 50mM	 lovastatin	 stock	was	 added	 to	300µls	of	DMSO	and	mixed	on	a	vortex	for	few	seconds.	This	was	then	added	to	E3	and	tricaine	solution.	The	final	concentration	of	lovastatin	was	4µM	and	that	of	tricaine	was	.66mg/ml.	
2.8.4	DMSO	40	mls	of	clear	E3	were	pipetted	out	into	a	falcon	tube.	300µls	of	DMSO	(Sigma-Aldrich)	were	added	to	E3.		
2.9	Treatment	groups:	The	double	transgenics	isolated	were	divided	equally	into	following	treatment	groups	
• 	Treated	with	DMSO	only	
• 	Treated	with	Lovastatin	4µM	
• 		Treated	with	tricaine	(0.66mg/ml)	only	
• 		Treated	with	Lovastatin	(4µM)	+	tricaine	(0.66mg/ml)	
• 		Standard	control	morpholino	injected	
• 		Tnnt2	morpholino	injected.	All	 the	 above	 groups	 were	 incubated	 in	 respective	 treatment	 solutions	 overnight	 at	280C.	
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	2.10	Imaging	embryos	for	GFP	fluorescence	As	will	 be	 discussed	 in	 chapter	 3	 the	 development	 of	 the	 screen	went	 through	 three	phases.	
2.10.1	Phase	1	Imaging	on	Axio-Zoom	V16	fluorescence	stereomicroscope	(Zeiss)	
2.10.1.1	Materials		
• 2dpf	embryos	
• Plastic	pipettes	(Oxford	Lab	Equipment)	
• Seeker	
• Watch	glass	
• Zeiss		Axio	Zoom	V16	fluorescence	stereomicroscope	(Zeiss)	
• ZenPro	(Zeiss)	software	
2.10.1.2	Method	0.5ml	 to	 1ml	 of	 tricaine	was	 added	 to	 each	 petri	 dish	 containing	 embryos	 in	 various	treatment	groups.	5	embryos	were	randomly	selected	 from	each	group	and	 imaged	as	follows.	Each	 embryo	was	 transferred	 into	 a	watch	 glass	with	 a	drop	of	 clear	E3.	 	 Seeker	was	used	to	line	up	the	embryos	in	a	horizontal	plane	under	the	microscope.		On	a	Axio	Zoom	V16	fluorescent	stereomicroscope	following	settings	were	used	to	acquire	images	Magnification		75%	Exposure	 		 5400	milliseconds	White	settings	 16383	Black	settings		 3000	Gamma	set	to		 1.0	
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Five	embryos	from	each	group	were	imaged.	The	metadata	of	 files	were	stored	as	 	 .czi	files	 (Zenpro,	 Zeiss).	 All	 the	 images	 were	 opened	 using	 FIJI	 software.	 Images	 were	analysed	 to	 measure	 integrated	 density	 (fluorescence)	 and	 saved	 as	 jpegs	 for	reconstruction	and	reproduction.		The	 data	 obtained	 was	 analysed	 using	 GraphPad	 Prism	 software.	 Mean	 integrated	densities	and	Standard	error	of	means	(SEM)	were	calculated.	The	results	were	further	analysed	using	Ordinary	one-way	ANNOVA.			
2.10.2	Phase2	Assessing	plate-reader	feasibility	
2.10.2.1	Materials	
• 2	dpf	embryos	
• Black-walled	clear	bottomed	96	well	plate	(Greiner)	
• P200	micropipettes	and	pipette	tips	(	World	Precision	Instruments)	
• Tricaine	stock	solution	(Sigma-Aldrich)	
• A	white	board	(workstation)	
• Seekers	
• Hairtools		
• Thermacol	box		
• ImageXpress	plate-reader	(Molecular	Devices)	
• MetaXpress5.0	software	for	analyzing	images.	
2.10.2.2	Method	A	 black-walled	 clear	 bottom	 96	well	 plate	 (Greiner)	 was	 placed	 on	 a	 lit	 white	 board	workstation.	A	plate	plan	was	noted	down.		Three	embryos	from	different	treatment	groups	were	placed	in	each	well	of	the	96	well	plate	in	225µls	of	clear	E3	medium.	25µls	of	tricaine	(4mg/ml)	were	pipetted	into	each	
	 		 	 53		
well.	Embryos	were	moved	to	the	centre	of	the	well	using	a	hair-tool.	96	well	plate	was	placed	in	a	polystyrene	box	to	avoid	temperature	changes	and	spillage.	96	 well	 plate	 was	 loaded	 onto	 ImageXpress,	 (Molecular	 Devices)	 high	 throughput	fluorescence	plate-reader.					Following	settings	in	the	plate	acquisition	part	of:	Objective:		 	 2X	Exposure:	 	 1500	milliseconds	for	RFP	(red)	channel		 	 	 2000	milliseconds	for	GFP	(green)	channel	Focus			 	 Focus	on	well	bottoms	Each	well	was	divided	into	four	quadrants	to	capture	all	the	embryos	in	the	well.		Once	 pretreatment	 images	were	 acquired,	 200µls	 of	 	 E3	medium	was	 pipetted	 out	 of	each	well,	leaving	behind	50	microlitres	of	E3	medium.	100	µls	of	E3	medium	was	added	to	each	well	and	a	further	100	µl	of	treatment	solutions	of	lovastatin,	tricaine,	lovastatin	and	tricaine	and	DMSO	were	added	to	the	wells	as	per	the	plate	plan.	The	96	well	plate	was	incubated	overnight	at	280	C.		Images	 were	 analysed	 using	 MetaXpress	 5.0	 software.	 The	 multi-wavelength	 cell		scoring	 (MWCS)	 algorithm	 (described	 later)	provided	 in	 the	 software	was	 customized	and	used	to	calculate	integrated	intensity	of	each	quadrant.	Integrated	intensity	for	each	well	 was	 calculated	 by	 adding	 the	mean	 integrated	 intensity	 of	 each	 quadrant.	 	 Data	acquired	 was	 analysed	 using	 GraphPad	 Prism	 statistical	 software.	 	 Mean	 integrated	densities	and	Standard	error	of	means	(SEM)	were	calculated.	The	results	were	further	analysed	using	Ordinary	one-way	ANNOVA.			
	
2.10.3	Phase	3	Using	the	assay	for	screening	drugs	from	Spectrum	(SP100122)	library		
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2.10.3.1Materials	
• Double	transgenic	2	dpf	embryos	
• Black-walled	clear	bottomed	96	well	plate	(Greiner)	
• Spectrum	SP100122	drug	library	test	plate	(Sigma)	
• P200	micropipettes	and	pipette	tips	(World	Precision	Instruments)	
• Tricaine	(stock	solution)	(Sigma-Aldrich)	
• A	back-lit	whiteboard	workstation	
• Seekers	
• Hairtool		
• Thermacol	box		
• ImageXpress	plate-reader	(Molecular	Devices)	
• MetaXpress5.0	software	for	analyzing	images.	Spectrum	 drug	 library	 is	 dispensed	 in	 sealed	 96	 well	 plates.	 Columns	 1	 and	 12	 are	mostly	empty.	Wells	A01,	A12,	H01	and	H12	contain	DMSO	only.	Thus	each	plate	has	80	drugs	for	screening	purposes.	Each	well	contains	5µls	of	a	drug	in	25mM	concentration.			
2.10.3.2Method		After	 noting	 down	 a	 plate	 plan,	 spectrum	 library	 test	 plate	 was	 thawed	 at	 room	temperature.	 95	 µls	 of	 clear	 E3	 were	 added	 to	 each	 well	 to	 make	 a	 total	 volume	 of	100µls.	 1dpf	 embryos	 were	 screened	 for	 double	 transgenic	 embryos.	 Three,	 30	 hpf	(hours	post	fertilization)	embryos	were	placed	in	wells	of	a	96	well	plate	in	150mls	of	E3.	100	µls	of	drug	solution	was	added	to	respective	wells.	The	96	well	plate	was	given	a	good	shake	to	achieve	good	mixing	of	the	drug	with	E3	in	the	well.	This	gave	a	2.5	times	dilution	 to	 give	 a	 final	 concentration	 of	 10µM.	 The	 96	 well	 plate	 was	 placed	 in	 an	incubator	overnight	at	280	C.		
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On	 day	 2,	 25	 µls	 of	 tricaine	 (4mg/ml)	 was	 added	 to	 each	 well	 to	 anaesthetize	 the	embryos.	A	hair-tool	was	used	to	bring	the	embryos	to	the	centre	of	the	wells	 for	best	capture	 while	 imaging.	 Images	 were	 acquired	 on	 ImageXpress	 (Molecular	 Devices)	fluorescent	 plate-reader	 using	 the	 same	 settings	 as	 were	 used	 for	 acquiring	pretreatment	 images.	 Images	 were	 reconstructed	 using	 FIJI	 (NIH)	 and	 Powerpoint	(Microsoft)	software	programmes.	The	 images	 thus	 obtained	 were	 analysed	 using	 MetaXPress	 5.0	 software	 using	 a	customized	MWCS	(multi	wavelength	cell	scoring)	algorithm.	 	 Intergrated	intensity	for	each	 well	 was	 calculated	 and	 data	 acquired	 was	 analysed	 using	 GraphPad	 Prism	software.	 Mean	 integrated	 density	 and	 standard	 error	 of	 mean	 was	 calculated.	 The	results	were	further	analysed	using	One	way	ANNOVA	statistical	test.				
2.11	Algorithms	used	for	Image	analysis.			
2.11.1	Simple	threshold	technique	Initially,	 I	used	FIJI	software	to	analyse	the	 images.	 I	used	the	“Threshold	method”	the	simplest	form	of	segmentation	techniques	for	image	analysis.			
2.11.2		Customised	segmentation	algorithm.	MetaXpress	 5.0	 software	was	used	 to	 analyse	 images	 and	quantify	GFP	 florescence.	 It	was	 very	 evident	 after	 initial	 image	 acquisition	 and	 analyzing	 using	 the	 threshold	techniques	that	there	were	issues	of	autofluorescence,	particularly	in	the	yolk	sac	area	of	 zebrafish	 embryos.	 To	 prevent	 this	 over-estimation	 of	 fluorescence	 I	 used	segmentation	 methods	 to	 customize	 an	 algorithm,	 which	 excluded	 the	 yolk	 sac	 area	from	fluorescence	quantification.		This	algorithm	used	an	initial	red	fluorescent	protein	image	which	defined	the	zebrafish	vasculature.	A	segmentation	image	of	the	vasculature	
	 		 	 56		
was	thus	created.	Images	taken	with	a	green	filter	for	GFP	fluorescence	were	segmented	as	well	The	two	images	were	subtracted.	The	final	image	as	shown	in	the	figure	below	was	 used	 to	 measure	 GFP	 expression	 in	 the	 vasculature	 avoiding	 areas	 of	autofluorescence.															
	
	
	
Figure	2.7	Segmentation	algorithm	images.	Image	panels	showing	different	steps	in	developing	a	segmentation	algorithm	to	create	a	mask	of	zebrafish	vasculature.	The	mask	thus	created	is	superimposed	on	GFP	picture	to	calculate	fluorescence,	avoiding	areas	of	auto-fluoresence.					A. RFP	segmentation	image	B. GFP	segmentation	image	C. Masked	image.	
AA	
B	
c	
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	I	soon	found	that	this	algorithm	would	work	only	if	we	used	only	one	zebrafish	embryo	per	well.	If	more	than	one	fish	was	imaged	in	one	well,	we	had	to	line	the	fish	perfectly	to	 be	 able	 to	 use	 this	 subtraction	 algorithm.	 For	 a	 high	 throughput	 assay	 this	 would	prove	to	be	cumbersome	and	time	consuming.		Therefore	we	customized	Multi-Wavelength	Cell	Scoring	(MWCS)	algorithm	which	was	more	 efficient	 and	 easy	 to	 use	 for	 our	 assay.	 This	 was	 also	 based	 on	 segmentation	concept.	 This	 algorithm	 is	 used	 in	 cell	 fluorescence	 assays.	 	 The	 steps	 involved	 in	creating	this	algorithm	are	as	follow	
• Select	RFP	image	which	is	called	all	nuclei	
• Specify	the	size	range	of	the	nuclei	
• Choose	the	second	image	that	contains	positive	stain,	which	is	GFP	in	this	case.	
• Select	stain	area		
• Specify	the	size	and	range	of	cells.		This	 algorithm	 identifies	 GFP	 positive	 areas	 as	 cells	 of	 various	 sizes.	 The	minimum	 and	 maximum	 width	 helps	 the	 software	 to	 determine	 what	 is	considered	a	GFP	positive	cell.	A	range	of	intensity	is	determined	by	hovering	the	cursor	over	 the	 lowest	 intensity	GFP	positive	cell	and	the	highest	 intensity	GFP	positive	cell.	This	 is	usually	much	above	the	background	fluorescence.	 	Defining	these	parameters	helps	the	software	to	calculate	GFP	signal	that	is	not	affected	by	background	fluorescence.		
• Perform	 a	 multi-parameter	 analysis	 to	 obtain	 wavelength	 specific	 average	intensity	of	GFP	positive	cells.	A	line	graph	function	was	used	to	assess	background	intensity.	It	was	also	used	to	define	the	limits	of	the	gray	scale	values	in	the	GFP	image	for	calculations.		
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Figure:2.8	Multi-Wavelength	Cell	Scoring	in	our	model.			Image	A.	GFP	(G	Fluorescent	Protein)	image	showing	GFP	positive	areas.	Auto-fluorescence	can	be	seen	in	yolk	sac	and	the	tail	areas.	This	was	used	as	second	image.	Image	B:	RFP	(Red	Fluorescent	Protein)	image	showing	vasculature	in	2dpd	embryos.	This	was	used	as	the	all	nuclei	image	in	the	algorithm	Panel	C:	The	right-most	image	in	the	panel	shows	the	areas	in	which	the	GFP	stain	was	calculated.	It	is	obvious	from	the	image	that	the	areas	of	auto-fluorescence	were	avoided.				
A	 B	
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	Chapter	3	Results	and	Development	of	Assay		
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3.1	Introduction	
	Zebrafish	 are	 increasingly	 used	 for	 initial	 drug	 screening	 as	 alluded	 to	 earlier.	Quantifying	fluorescence	emitted	by	tagged	reporter	genes	is	increasingly	used	in	whole	organism	drug	screening	(White	et	al.,	2016).	I	used	a	double	transgenic	(klf2a:GFP;	kdrl:RFP)	zebrafish	(	Danio	rerio)	line,	developed	in	 our	 laboratory,	 to	 develop	 an	 assay	which	 could	 lead	 to	 a	mid	 to	 high	 throughput	whole	organism	screening.		
3.2		Development	of	assay			This	assay	was		developed	in	the	following	steps.	These	are	1. Finding	the	most	feasible	imaging	method	2. Finding	optimal	Lovastatin	concentration	3. Developing	positive	and	negative	controls	4. Customizing	an	algorithm	for	quantifying	GFP	fluorescence.	5. Actual	drug	screening	from	Spectrum	Drug	Library	(Sigma)		
3.2.1	Step	1:	Optimizing	imaging	method	
3.2.1.1:	Comparing	96	well	plate	with	384	well	plate.	To	assess	images	taken	in	a	384	well	plate	and	a	96	well	plate,	I	compared	the	images	of	the	embryos	in	a	384	well	and	a	96	well	plate.	The	images	of	the	embryos	that	were	in	focus	were	comparable.	Similarly	embryos	presenting	themselves	dorsally	or	ventrally	were	comparable.			 	
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Figure	3.2	Images	of	2dpf	embryos	of	positive	and	negative	controls	
in	a	384	well	plate.	Representative	images	of	2dpf	embryos	of	different	treatment	groups	in	a	384	well	plate.		
A. DMSO	treated.			 	 	 B.	Lovastatin	treated															C.	Lovastatin	+	Tricaine	treated							D.	Tricaine	treated						 E.	Tnnt2	morpholino	injected		 F.	Control	morpholino	injected	Scalebar		(3.22µm	=1	pixel)	
Figure	3.1		Presentation	of		embryos	
in	microtitre	plates.	Images	showing	possible	presentations	when	imaged	in	a	microtitre	plate			A. Dorsal	presentation	B. Ventral	presentation	C. Lateral	presentation		
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														However,	embryos	could	not	be	manipulated	into	a	more	lateral	position	in	a	384	well	plate,	I	decided	to	use	96	well	plate	with	clear	bottom	and	black	walls.				
3.2.1.2		Using	orientation	tool	for	imaging.	To	 further	 find	 an	 optimal	 method	 of	 imaging	 zebrafish	 embryos,	 I	 compared	 the	following	two	methods.	a. Direct	imaging	of	embryos	immersed	in	clear	E3	solution	with	tricaine	in		96	well	plate	with	black	walls	and	a	clear	bottom	(Greiner).		Images	were	obtained	using	ImageXpress	(Molecular	Devices)	plate	reader	using	a	2X	objective.		
Figure	3.3	Graph	comparing	the	presentation	of	zebrfish	embryos		in	
96	and	384	well	plates.		The	two	column	graphs	comparing	images		obtained	from	embryos	in	a	96	well	plate	(left	graph)	and	384	well	plate	(right	graph).	There	was	no	obvious	difference	in	two	techniques.	(none	of	the	embryos	were	found	in	dorsal	presentation	in	the	384	well	plate)	
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b. 96	well	 compatible	 zebrafish	 orientation	 tools	 have	 been	 described.	 I	 used	 3D	printed	molds	 to	make	 agarose	 wells	 in	 a	 96	 well	 plate	 to	 orientate	 zebrafish	embryos	for	optimal	imaging.		
	
	
	
	
	
	
	
	
	
		
	
Figure	3.4	Representative	Images	of	embryos	using	different	mounting	
methods.		Left	panel	shows	a	representative	RFP	and	GFP	images	of	embryos	imaged	in	a	96	well	plate	containing	clear	E3	medium.		Right	panel	shows	RFP	and	GFP	images	in	agarose	molds	made	in	wells	using	orientation	tools.			
Figure	3.5	Column	graph	comparing	the	quality	of	images	acquired	
with	two	techniques.	Column	graph	showing	obvious	superiority	of	images	obtained	by	imaging	embryos	with	clear	E3	medium	in	the	well	as	compared	to	the	images	obtained	by	placing	embryos	in	agarose	wells.			
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		I	found	the	following	pitfalls	in	using	agarose	molds	for	imaging,	a. Some	agarose	came	out	stuck	to	the	molds	when	plastic	molds	were	removed.	b. On	adding	E3	to	the	wells	the	agarose	molds	rotated	in	the	wells	thus	resulting	in	mal-orientation	of	zebrafish	embryos.	c. On	adding	E3	embryos	floated	out	of	the	molds.	d. Prodding	embryos	into	the	molds	was	time	consuming.	
Conclusion	The	 obvious	 conclusion	 from	 the	 above	 experiment	 was	 that	 imaging	 2dpf	 zebrafish	embryos	 in	agarose	molds	was	not	 feasible.	Therefore,	 I	 transferred	 the	embryos	 into	
Figure	3.6	Photograph	of	a	96	well	plate	with	agarose	molds	Image	of	a	96	well	plate	bottom,	showing	a	well-orientated	agarose	mold	(short	white	arrow).	Many	of	the	agarose	molds	are	mal-rotated	(long	white	arrow),	precluding	optimal	imaging	of	the	embryos.		
	
Correctly	orientated	mold	 Wrongly	orientated	mold	
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the	 96	well	 plate	 by	 pipetting	 out	 embryos	 in	 clear	 E3	medium	 and	 let	 the	 embryos	settle	 on	 to	 the	 clear	 glass	 bottom	 of	 the	 well.	 I	 also	 used	 a	 hair	 tool	 to	 orientate	zebrafish	embryos	horizontally.	25	micro-litres	of		stock	solution	of	Tricaine	was	added		to	 each	 well	 to	 anaesthetize	 the	 embryos	 whilst	 imaging.	 This	 facilitated	 the	 pre-treatment	and	post-treatment	imaging.	
	
3.3	Step	2.	Finding	optimal	Lovastatin	concentration.	
	
	
3.3.1	 Comparing	 relative	 increase	 in	 GFP	 fluorescence	 pre	 and	 post	 treatment	
with	lovastatin.				1day	 post	 fertilization	 (dpf)	 embryos	 were	 divided	 into	 four	 groups.	 Each	 group	consisted	of	five	embryos.	One		embryo	from	each	group	was	plated	in	a	small	petri	dish	and	labeled.	DMSO	controls	were	labeled	as	DMSO	1,	DMSO	2	and	so	forth.	 	Lovastatin	treated	 embryos	 were	 labeled	 as	 Lova	 21,	 Lova22	 and	 so	 forth.	 In	 lovastatin	 treated	groups	 the	 first	 number	 was	 concentration	 in	 µM	 and	 second	 digit	 was	 the	 number	assigned	to	the	embryo.	The	embryos	were	imaged	on	a	fluorescence	stereomicroscope	before	 any	 treatment.	 	 The	 embryos	 were	 treated	 with	 varying	 concentrations	 of	Lovastatin	 and	 control	 group	 was	 treated	 with	 DMSO.	 Embryos	 were	 incubated	overnight	and	post-treatment	images	were	obtained.	FIJI	(Image	J)	was	used	to	quantify	fluorescence	and	GraphPad	Prism	software	was	used	for	analyzing	the	data.	All	 images	were	acquired	on	 the	 fluorescent	 stereomicroscope	 fluorescent	microscope	(Zeiss	Axio	Zoom	V16)	using	following	settings,	Exposure	was	 set	 at	 5400	milliseconds.	 Black	 and	white	 values	were	 set	 at	 3000	 and	16383	respectively.	Gamma	was	set	at	1.					
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										To	answer	the	question	whether	the	increase	in	fluorescence	was	simply	as	a	result	of	normal	 growth	 in	 the	 embryos	 from	1dpf	 stage	 to	 2dpf	 stage.	 The	 panel	 of	 images	 in	figure	 3.6	 shows	 similar	 fluorescence	 in	 1dpf	 embryos	 in	 all	 the	 groups.	 There	 is	 an	obvious	 increase	 in	 green	 fluorescence	 in	 2dpf	 embryos	 treated	 with	 different	concentrations	of	Lovastatin	as	compared	with	2dpf	embryos	treated	with	DMSO	alone.		
Figure	3.7	Picture	panels	showing	relative	increase	in	GFP	fluorescence	in	
controls	and	Lovastatin	treated	embryos.	Comparing	relative	increase	in	fluorescence	in	lovastatin	treated	zebrafish	embryos	and	DMSO	treated	controls	at	1dpf	stage	(pretreatment)	and	at	2dpf	stage	(post	treatment).	Upper	images	in	panels	are	pre-treatment	images	and	lower	images	are	post-treatment	images.		
A.	DMSO	controls	B.	Lovastatin	2µM	C.	Lovastatin	3µM	D.	Lovastatin	4µM	{Image	acquisition	Settings	:	Exposure	5400	milliseconds,	Black	3000,	White	16383	Magnification	set	at	75}			
Figure	3.8	Measuring	
Fluorescence.		Rectangular	area	over	body	of	embryo	was	selected	for	measuring	GFP		fluorescence	using	FIJI	(	ImageJ)		
A	
B	
C	
	
D	
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Figure	3.9	Column	graphs	of	pre	and	post	treatment	fluorescence		Graphs	showing	the	level	of	GFP	fluorescence	in	individual	zebrafish	embryos	pre	(1dpf)	and	post-treatment	(2dpf)	with	different	concentrations	of	Lovastatin.		(2dpf	embryos).	(p=ns)		
Figure	3.10:	Scatter	plot	of	pre	and	post	treatment	fluorescence.	Comparing	1dpf	(pretreatment)	and	2dpf	(post-treatment)	fluorescence	in	different	treatment	groups	.	(p=ns).		DMSO	(Dimethyl	sulphoxide),	Lova	(Lovastatin;	the	digits	at	the	end	show	the	concentration	of	lovastatin	in	µM.		(Mean	corrected	total	fluorescence	(pre/post	treatment):		DMSO	(1742316/2610477),	Lovastatin	2µM	(164663/2863135),	Lovastatin	3µM	(	1974817/3363774),		Lovastatin	4µM	(1997505/3130338).			{(p=ns)	One	way	ANOVA}			
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Conclusion	The	above	set	of	data	showed	that	 the	relative	 increase	 in	 fluorescence	was	greater	 in	lovastatin	 treated	 embryos	 as	 compared	 to	 the	DMSO	 treated	 embryos	 in	 the	 control	group.		Though	this	increase	was	not	statistically	significant.		
3.3.2	Mapping	a	dose	response	curve	 to	 find	out	 the	optimal	Lovastatin	dose	 for	
positive	controls.	After	 screening	 and	 identifying	 double	 transgenic	 embryos,	 I	 treated	 1dpf	 zebrafish	embryos	with	 Lovastatin	 in	 concentrations	 ranging	 from	1	 µM	 to	 5	 µM.	 The	 embryos	were	then	incubated	at	280	C	overnight	for	16	hours.	The	control	group	was	treated	with	DMSO	alone.		Images	of	different	groups	(n=5)	and	controls	(n=5)	were	obtained	using	fluorescent	 stereomicroscope	 (Zeiss	 Axio	 Zoom	 V16)	 	 	 and	 Zenpro	 (Zeiss)	 software.	Images	 thus	 obtained	 were	 analysed	 using	 FIJI	 (National	 Institutes	 of	 Health,	 USA)	software.	 Corrected	 total	 fluorescence	 was	 calculated	 for	 each	 group	 and	 the	 results	were	statistically	analysed	using	ordinary	one	way	ANOVA		in	GraphpadPrism.			 							
Figure	3.11	Dose	response	curve	for	Lovastatin.	Vertical	picture	panels	showing	increase	in	GFP	fluorescence	in	2dpf	embryos	treated	with	increasing	doses	of	Lovastatin	when	compared	with	DMSO	treated	embryos	(first	vertical	panel).			
DMSO	 Lovasta,n	2µM	 Lovasta,n3µM	 Lovasta,n4µM	 Lovasta,n	5µM	
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				I	 repeated	 the	 experiment	 using	 4µM,	 5µM,	 6µM,	 7µM	 and	 8µM	 concentrations	 of	lovastatin.	 The	 aim	 was	 to	 find	 the	 concentration	 of	 lovastatin	 that	 could	 result	 in	maximum	 increase	 in	 GFP	 signal.	 I	 dpf	 embryos	 were	 treated	 with	 the	 above	concentrations	of	lovastatin	and		were	incubated	overnight	at	28	0C	with	DMSO	treated	controls.	 2	 dpf	 embryos	 from	 each	 group	 (n=5)	 were	 imaged	 on	 the	 fluorescent	stereomicroscope	(Axio	Zoom	V16,	Zeiss).	 	Corrected	total	 fluorescence	was	calculated	by	 analysing	 the	 images	 using	 FIJI	 (NIH)	 software.	 Statistical	 analysis	was	 performed	using	One-way	ANOVA	in	Graphpad	Prism	software.	
Figure	3.12	Lovastatin	dose	response	graph		Scatter	plot	showing	significant	increase	in	corrected	total	fluorescence	in	2dpf	embryos	treated	with	increasing	concentrations	of	lovastatin.	Graph	showing	a	maximum	increase	in	mean	GFP	fluorescence	(105621625)	in	embryos	treated	with	4µM	Lovastatin	as	compared	with	DMSO	(546555)		
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Conclusion	The	dose	response	plot	showed	that	there	was	no	linear	correlation	between	lovastatin	dose	 and	 GFP	 signal.	 Results	 revealed	 that	 maximum	 GFP	 signal	 was	 obtained	 when	lovastatin	was	used	in	4µM	concentration.	For	subsequent	experiments	Lovastatin	was		used	in	4µM	concentration	as	a	positive	control.		
	
Figure	3.13	Lovastatin	dose	response	using	higher	concentrations	
Increased	expression	of	GFP	in	2dpf	embryos	treated	with	Lovastatin	in	4µM	to	8µM	concentration	as	compared	to	DMSO	treated	controls	(Lowest	panel).			
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3.4	Developing	positive	and	negative	controls	We	already	know	that	klf2	is	a	mechano-transduction	gene	expressed	in	endothelial	cells	and	 responds	 to	 flow	 patterns	 in	 blood	 vessels.	 Laminar	 flow	 patterns	 enhance	 klf2	expression	 and	 non-laminar	 or	 turbulent	 flow	 suppresses	 klf2	 expression.	 If	 the	zebrafish	do	not	develop	any	blood	flow,	vascular	klf2	expression	is	almost	completely	suppressed.	 Statins	 are	 known	 to	 increase	 klf2	 expression	 through	 flow	 independent	pathways	by	inhibiting	Rho	enzymes.		I	used	the	above	mentioned	characteristics	 to	develop	positive	controls	 involving	 flow	and	non	flow	dependent	pathways	for	Klf2a	expression.	Zebrafish	embryos	were	treated	with	Lovastatin	to	augment	klf2a	expression.	I	also	used	tnnt2	morphants	developed	by	
Figure	3.14	Lovastatin	dose-response	graphs	for	higher	
concentrations			A	scatter	plot	showing	mean	corrected	total	fluorescence	in	2dpf	embryos.	The	graph	shows	a	significant	increase	of	GFP	fluorescence	in	embryos	treated	with	lovastatin.	Maximum	increase	is	seen	in	embryos	treated	with	4µM	concentration	of	Lovastatin	(597453880)	as	compared	with	DMSO	treated	group	(262388980).				
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injecting	1-2	cell	stage	embryos	with	tnnt2	morpholino.	These	embryos	do	not	develop	any	blood	flow	due	to	loss	of	myocardial	development	resulting	in	significant	decrease	in	klf2a	expression	in	vascular	endothelium.		I	 also	 treated	 1dpf	 embryos	 with	 tricaine,	 a	 local	 anaesthetic,	 to	 arrest	 cardiac	contractility	 and	 thus	 blood	 flow.	 Another	 group	 of	 1dpf	 embryos	 was	 treated	 with	tricaine	 and	 lovastatin	 to	 assess	 direct	 effect	 of	 lovastatin	 on	 klf2a	 expression	 in	 the	absence	of	blood	flow.		Two	groups	of	1dpf	zebrafish	embryos	were	used	as	negative	controls.	One	group	was	treated	with	DMSO	and	the	second	injected	with	the	standard	control	morpholino.		
	
3.4.1	 Validating	 positive	 and	 negative	 controls,	 by	 examining	 effect	 of	 flow	 and	
Lovastatin	on	GFP	fluorescence	in	2dpf	zebrafish.	
3.4.1.1	Using	a	fluorescent	stereomicroscope	(Axio	Zoom	V	16	Zeiss)	After	embryo	collection,	I	injected		two	groups	of	1-2	cell	embryos	with	1nanoliter	(nl)	of	 standard	 control	 morpholino	 (0.2mM)	 and	 1	 nanolitre	 (nl)	 of	 	 tnnt2	 morpholino	(0.2mM).		The	rest	of	the	embryos	were	plated	in	groups	of	50	embryos	per	petri	dish.	All	the	embryos	were	incubated	at	280	C	overnight	in	E3	medium	with	methylene	blue.		1dpf	embryos	in	all	the	groups	were	screened	for	green	and	red	fluorescence.	Embryos	positive	for	red	and	green	fluorescence	were	divided	into	following	treatment	groups,	i.	DMSO	only	treated	ii.	Control	morpholino	injected	iii.	Tricaine	only		iv.	Tricaine	+	lovastatin	treated		v.	Lovastatin		only		vi.	tnnt2	morpholino	injected.	
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Five	embryos	from	each	group	were	imaged	for	green	fluorescence	on	stereomicroscope	(Axio	Zoom	V16	by	Zeiss).	Zenpro		(Zeiss)	software	was	used	to	acquire	images.		Images	thus	obtained	were	analysed	using	FIJI	(ImageJ)	software.	The	total	fluorescence	values	thus	measured	can	be	affected	by	autofluorescence,	as	 in	the	yolk	area	of	the	embryos	and	 by	 background	 fluorescence.	 In	 order	 to	 remove	 these	 errors	 corrected	 total	fluorescence	was	calculated	as	follows	1. I	selected	a	rectangular	area	of	 interest	over	4-5	myotomes	in	the	trunk	area	of	the	2dpf	embryo.		2. In	FIJI,	I	set	the	analyse	menu	to	measure	area	of	the	rectangle	drawn,	integrated	density	of	the	area	and	mean	gray	scale	value.	3. I	repeated	these	measurements	by	drawing	a	rectangle	of	the	same	size	outside	the	embryo.	This	gave	the	values	for	the	background	fluorescence.	4. Corrected	total	fluorescence	was	calculated	using	the	formula	Corrected	 total	 fluorescence	 =	 Total	 Integrated	 density	 –	 (Area	 of	 embryo	selected	X	Mean	gray	scale	value	of	the	background)		Total	corrected	fluorescence	was	calculated	over	a	selected	area	over	the	aortic	region	in	 the	body	of	 2	dpf	 embryos.	 Corrected	 total	 fluorescence	was	 also	 calculated	over	 a	selected	area	over	the	body	including	myotomes	of	2dpf	embryos.	An	area	of	same	size	was	 used	 for	 fluorescence	 calculations	 in	 all	 the	 embryos	 imaged.	Data	 thus	 obtained	was	analysed	using	One-way	ANNOVA	test	in	GraphPad	Prism	statistical	software					
Corrected	total	fluorescence	=		
Total	 Integrated	density	–	(Area	of	embryo	selected	X	Mean	
gray	scale	value	of	the	Background)			
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Figure	3.15	Measuring	total	corrected	fluorescence.		Panel	A:		Shows	a	rectangular	area	drawn	over	aorta	to	calculate	total	fluorescence.	Similar	area	drawn	outside	the	embryo	(left	image)	was	used	to	measure	background	fluorescence.	Panel	B:	Rectangular	areas	drawn	over	myotomes	to	calculate	total	fluorescence	and	background	fluorescence.				
DMSO	
Lovasta,n	
4µM	
Tricaine(	0.66mg/ml)	
Lovasta,n	4µM	
Tricaine	(0.66mg/ml)	
Control		
Morpholino	
Tnnt2		
Morpholino	
Images	taken	at	75X	with	Exposure	of	7500	ms,		
Black	seNngs	of	3000,	White	seNng		of	16383	and	γ	of	1.			
Figure	3.16	Image	panels	of	positive	and	negative	control	groups	
obtained	using	a	fluorescent	microscope..	Image	panels	showing	GFP	expression	in	positive	control	groups	(lovastatin	4µM,	Tnnt2	morpholino	injected,	tricaine	an	tricaine	with	lovastatin)	and	negative	controls	(DMSO	treated	and	control	morpholino	injected).	Lovastatin	treated	embryos	show	increased	green	fluorescence,		Tnnt2	morpholino	injected	and	tricaine	treated	embryos	show	lower	green	fluorescence	as	compared	to	negative	controls.		
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			I	 also	 explored	 the	 possibility	 of	 using	 Resveratrol	 as	 another	 positive	 control.	Resveratrol,	 a	 plant	 sterol,	 is	 a	 nicotinamide	 dinulcleotide	 dependent	 deacetylase,	known	to	induce	KLF2	through	activation	of	SIRT1	(Sirtulin	1).	SIRT1	acts	on	MEK5	and	MEF2	 pathways	 thereby	 upregulating	 KLF2	 	 in	 HUVECs	 (Human	 Umbilical	 Vascular	Endothelial	Cells	(Gracia-Sancho	et	al.,	2010).	I	was	not	able	to	show	any	significant	increase	in	GFP	fluorescence	in	2dpf	embryos	that	were	treated	with	resveratrol	for	sixteen	hours	prior	to	imaging.		Resveratrol	was	used	in	concentrations	of	20	µM,	40	µM,	60	µM,	80	µM	and	100	µM.	This	result	was	contrary	to	that	seen	by	Gracia-	Sancho	et	al.		
Figure	3.17:	Graphs	showing	Corrected	total	fluorescence.		Graphs	replicating	observations	in	the	image	panels	in	figure	3.16.		
Left	graph	shows	significant	increase	in	corrected	total	fluorescence	in	lovastatin	treated	2dpf	embryos	when	fluorescence	was	measured	over	the	body	of	zebrafish	embryo.		
Right	graph	shows	corrected	total	fluorescence	calculated	over	a	selected	area	over	aorta	to	measure	green	fluorescence	restricted	to	the	vasculature.	Again	Lovastatin	treated	embryos	had	significant	increase	in	GFP	fluorescence	as	compared	to	negative	controls.	
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Figure	3.18	Image	panels	of	resveratrol	treated	embryos	2dpf	embryo	treated		images	after	resveratrol	treatment	with	concentrations	varying	from	40	to	100	µM.			
A.	(DMSO	treated).	 	 	B.	Resveratrol	40µM		
C.	Resveratrol	60µM				 D.		Resveratrol	80	µM			
E.	Resveratrol	100µM	 	
Figure	3.19	Effect	of	Resveratrol	on	GFP	expression		Graphs	showing	no	increase	in	GFP	fluorescence	in	resveratrol	treated	groups	as	compared	to	DMSO	treated	controls.	
A	
B	
C	
D	
E	
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3.4.1.2		Validating	positive	and	negative	controls	on	plate-reader	To	develop	the	assay	further,	I	tested	the	feasibility	of	the	ImageXpress		plate-reader	for	validating	 the	 positive	 and	 negative	 controls.	 Three	 1dpf	 zebrafish	 embryos	 per	 well	were	placed	in	each	row	(n	=12)	of	a	96	well	plate	with	a	clear	bottom	and	black	walls	(Greiner).	 One	 row	 treated	 with	 DMSO	 (Dimethyl	 Sulfoxide)	 was	 used	 as	 a	 negative	control.	 Three	 further	 rows	were	 treated	with	1µM,	4µM	and	10µM	concentrations	of	lovastatin	and	used	as	positive	controls.	Embryos	were	 incubated	overnight	at	280C	in	250	µls	(microlitres)	of	DMSO	in	E3	and	1,	4	and	10	µM	concentrations	of	lovastatin	in	E3.		On	2dpf	25µls	of	tricaine	were	added	to	each	well.	Embryos	were	prodded	to	occupy	central	area	of	 the	wells	using	a	hair-tool.	 Images	were	obtained	on	 ImageXpress	high	throughput	plate-reader	using	a	2X	objective	with	exposure	times	of	1500	milliseconds	for	 red	channels	and	2000	milliseconds	 for	green	channel.	Each	well	was	divided	 into	four	quadrants	to	increase	the	possibility	of	capturing	images	of	all	three	embryos.	
			
	
Figure	3.19	Reconstruction	of	images	of	each	well	of	a	96	
well	plate.		
Left	panel	showing	the	images	of	four	quadrants	of	a	well.	
Right	panel	image	showing	a	reconstructed	well.	
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																Image	 analysis	 using	 MetaXpress	 5.0	 software	 and	 MWCS	 (multi	 wavelength	 cell	scoring)	 algorithm	 was	 able	 to	 read	 a	 significant	 increase	 in	 GFP	 expression	 in	 2dpf	embryos	treated	with	1µM,	4µM	and	10µM	concentrations	of	Lovastatin	for	15	hours	as	compared	 with	 DMSO	 treated	 controls.	 It	 was	 amply	 clear	 that	 ImageXpress	 plate-reader	was	able	to	replicate	the	results	obtained	by	imaging	on	a	stereomicroscope	and	quantifying	 fluorescence	using	 FIJI	 software.	Hence	 the	 assay	was	 taken	 to	 next	 stage	and	was	used	to	screen	drugs	from	Spectrum	library.	
Figure	3.21	Measuring	fluorescence	in	a	plate-reader		Panels	A	and	B	are	pre	and	post-treatment	images	of	DMSO	treated	control	group.		Panels	C	and	D	represent	pre	and	post	treatment	images	of	embryos	treated	with	4µM	lovastatin.			Settings	on	which	images	were	acquired:	Objective	2X,		Exposure	for	RFP	channel	1500	milliseconds,		Exposure	for	2000milliseconds		
A	
B	
C	
D	
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3.4.1.3	Quality	control	measures	To	assure	quality	control	of	 the	assay	I	calculated	“Z”	 factor	 for	the	assay.	Z	 factor	 is	a	measure	of	“statistical	effect	size”.	It	compares	the	mean	values	of		positive	or	maximum	signal	control	to	negative	or	minimum	signal	control.	“Z”	factor	was	calculated	using	the	following	formula		
Z	=	1-	3(	σp	+	σn	)/	µp	-	µn	
where	σp	is	standard	deviation	of	the	integrated	density	values	of	lovastatin	(4µM)	
treated	embryos	and	σn	is	the	standard	deviation	of	 integrated	density	values	of		
Figure	3.22	Scatter	plots	of	the	fluorescence	data	acquired	on	
ImageXpress.		
Right	Graph:	Scatter	plots	of	post	treatment	GFP	fluorescence	showing	significant	increase	in	post-treatment	(2dpf)	GFP	expression	in	embryos	treated	with	Lovastatin	as	compared	to	DMSO	controls.		
Left	graph:	Shows	pretreatment	(1dpf)	GFP	expression,	which	is	same	in	all	the	groups.	These	results	replicate	the	results	obtained	with	a	fluorescent	stereomicroscope.	
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DMSO	treated	controls,	and	µp		is	the	mean	integrated	density	of	lovastatin	treated	
embryos	and		µn	is	the		mean	of	the	integrated	density	of	DMSO	treated	controls.	I	obtained	a	value	of	0.17	for	Z.	(See	Appendix1).	This	qualified	my	assay	as	a	marginal	one.	 As	 is	 evident	 from	 the	 above	 formula	 that	 the	 Z	 prime	 calculation	 involves	 a	constant	factor	of	3.	This	is	based	on	the	assumption	that	the	distribution	is	normal,	and	99%	of	the	values	are	within	3	standard	deviations.		It	is	known	that,	in	high	throughput	screening	 there	 is	 a	 high	 chance	 of	 distribution	 to	 be	 non-normal.	 Also	 the	 extreme	values	 can	 adversely	 affect	 “Z”	 value	 resulting	 in	 a	 situation	 where	 the	 assay	 may	perform	well	in	actual	screening	and	the	Z	factor	is	unfavorable	{Zhang,	1999}		The	overcome	some	of	the	short-comings	mentioned	above,	a	relatively	new	statistical	parameter,	 Strictly	 Standardized	 Mean	 Difference	 (SSMD)	 is	 also	 used	 in	 high	throughput	screens.	I	calculated	the	SSMD	for	my	positive	and	negative	control	groups	using	the	following	formula.		
SSMD	(β)	=	µp	− 	µn	/	√σp2	+ 	σn2	
Where	µp	is	mean	value	of	positive	controls,	µn	is	 the	mean	value	of	the	negative	
controls,	σp2	is	the	variance	in	the	positive	controls	and	σn2	is	the	variance	of	the	
negative	controls.		SSMD	of	my	assay	was	4.5.		SSMD	not	only	ranks	the	size	effect	but	also	has	a	predictor	value	 for	 classifying	 effects.	 A	 value	 of	 4.5	 is	 classified	 as	 a	 very	 strong	 threshold	 for	positive	SSMD.				 		
Conclusion		The	 above	 experiment,	 statistical	 analysis	 and	 the	 quality	 control	 evaluation	 further	validated	the	feasibility	of		performing	drug	screen,	using	ImageXpress	plate-reader	for	mid	to	high	throughput	assays.		
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3.5	Mid	to	High	throughput	assay	for	Drug	Screening	Having	 established	 positive	 and	 negative	 controls	 and	 feasibility	 of	 plate-reader	 as	 a	screening	tool,	I	planned	a	mid-throughput	drug	screen	using	test	plates	from	spectrum	drug	library	(Sigma).	
3.5.1	Screening	of	drugs	from	Spectrum	SP100122	drug	library		Three	1dpf	 embryos	were	placed	 in	 each	well	 of	 a	96	well	 plate	 in	225	microlitres	of	clear	E3	solution	and	25	microlitres	of	tricaine	(0.66mg/ml).	All	wells	were	imaged	on	ImageXpress	high	throughput	plate	reader	using	a	2X	objective	and	exposures	fixed	to	2750	milliseconds	for	GFP(green	fluorescent	protein)	channel	and	1500	milliseconds	for	RFP	 (red	 fluorescent	protein)	 channel.	Once	pretreatment	 images	were	obtained	 fluid	was	aspirated	out	of	the	wells	and	1dpf	embryos	were	treated	with	10µM	concentration	of	drugs	 from	spectrum	 library	 test	plate	and	controls.	Total	volume	of	 the	 test	drugs	and	 E3	 medium	 in	 each	 well	 was	 250	 microlitres.	 The	 embryos	 were	 incubated	overnight.	 Twenty	 five	 microlitres	 of	 tricaine	 (4mg/ml)	 were	 added	 to	 each	 well.	Embryos	were	prodded	to	occupy	the	centre	of	the	wells	for	optimal	image	capture.	The	pre-treatment	and	the	post-treatment	images	were	acquired	using	the	same	settings	on	the	plate-reader.	Integrated	intensity	of	green	fluorescence	was	measured	by	using	MetaXpress	software.		Data	 thus	 obtained	was	 analysed	 using	 One	way	 ANOVA	 statistical	 tests	 in	 Graphpad	Prism	software.					
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Figure	3.23	Spectrum	library	drug	screening.	Representative	images	from	drug	screening	plates	DMSO	(D06,	C12)	Lovastatin	(A06,	B12)	and	Spectrum	drugs	(D02,	A06b).	Images	were	obtained	with	following	settings		Objective:	2X,	Exposure	GFP	channel:	2750	ms	and	Exposure	RFP	channel:	1500	ms		
	Figure	3.24	Integrated	intensity	of	different	drug	screen	
candidates.	Column	graph	comparing	GFP	fluorescence	(integrated	intensity)	of	2dpf	embryos	treated	with	Spectrum	library	candidates,	DMSO	and	lovastatin.	It	is	obvious	from	the	plot	that	the	screen	did	not	work	as	the	integrated	intensity	of	lovastatin	treated	embryos	is	lower	than	the	negative	controls	(DMSO	group).		Multi-Wavelenght	Cell	Scoring	algorithm	was	used	to	calculate	integrated	density		
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																	Integrated	intensity	of	green	fluorescence	was	measured	by	using	MetaXpress	software.		Data	thus	obtained	was	analysed	using	Graphpad	Prism	statistical	software.	The	above	results	show	a	failed	drug	screen.	In	the	above	column	graph	fluorescence	of	Lovastatin	 treated	positive	 controls	 is	 less	 than	 the	DMSO	 treated	negative	 controls.	 I	cross-checked	these	results	with	the	images	obtained	on	the	plate	reader.	The	reasons	that	came	to	light	by	looking	at	the	images	were,	fluorescence	caused	by	the	drug	under	investigation	 itself,	 as	 in	case	of	well	B03.	Lots	of	embryos	appeared	damaged.	One	of	the	possibilities	was	that	10µM	dose	for	screening	was	too	high	or	it	was	a	bad	batch	of	
Figure	3.25	Representative	images	of	drug	screen.	Images	of	wells	with	fluorescent	drug	(B03)	damaged	embryo	with	lots	of	fluorescence	(B11,	F07	and	E08)	Images	were	obtained	with	following	settings		Objective:	2X,	Exposure	GFP	channel:	2750	ms	and	Exposure	RFP	channel:	1500	ms		(Alpha-numeric	are	the	well	numbers).	
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embryos.	 	 In	 order	 to	 re-validate	 the	 controls,	 I	 repeated	 the	 experiment	 by	 blinding	positive	and	negative	controls	and	comparing	 the	 fluorescence	 to	Tnnt2	morphants.	 	 I	also	filled	some	wells	with	clear	E3	medium	only.		Using	the	values	of	integrated	density	from	these	wells	I	plotted	the	following	graphs	for	integrated	density	and	net	integrated	density.	 Net	 integrated	 density	 was	 calculated	 by	 subtracting	 the	 integrated	 density	values	 obtained	 from	 the	wells	 containing	 E3	medium	 only	 from	 the	 values	 obtained	from	the	wells	containing	treatments	A	or	B.	On	 analyzing	 the	 data	 for	 total	 and	 net	 integrated	 density.	 Treatment	 A	 significantly	increased	the	fluorescence	in	2dpf	zebrafish	embryos	as	compared	to	Tnnt2	morphants.	On	decoding,	treatment	“A”	was	lovastatin	in	4µM	concentration	and	treatment	“B”	was	DMSO	only.		This	further	endorsed	the	validity	of	controls.			 							 				
Figure	3.26	Blinded	positive	and	negative	controls.	Graphs	comparing	effects	of	Tnnt2	morpholino	injection,	treatment	A	and	treatment	B	on	GFP	expression	in	2dpf	embryos.	The	treatments	A	and	B	were	blinded	to	validate	positive	and	negative	controls.	Both	the	graphs	show	significant	increase	in	integrated	intensity	and	net	integrated	intensity	in	treatment	Group	A.		(Net	integrated	fluorescence	was	calculated	by	subtracting	integrated	density	values	of	the	wells	containing	E3	medium	only	from	integrated	density	values	of	the	wells	containing	treatments	A	or	B.	One	way	ANOVA	was	used	for	statistical	analysis.	)		On	decoding	treatment	A	was	lovastatin	in	4µM	concentration	and	treatment	B	was	DMSO.		
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				Next	 I	 repeated	 the	 drug	 screen	 using	 5µM	 concentration	 of	 drugs.	 The	 micro-assay	plate	containing	the	drugs	was	thawed	at	room	temperature.	200	µls	of	clear	E3	solution	were	added	to	each	well.	100	µls	were	used	to	treat	the	embryos	in	each	well.	150	mls	of	E3	 medium	 was	 	 added	 to	 each	 well	 achieving	 a	 5	 times	 dilution.	 25µls	 of	 tricaine	(6.6mg/ml)	was	added	to	each	well	before	 imaging.	Mean	integrated	intensity	of	wells	treated	 with	 	 DMSO	 was	 used	 as	 a	 negative	 control	 for	 comparison.	 Similarly	 mean	integrated	 intensity	 of	 wells	 containing	 Lovastatin	 treatment	 was	 used	 as	 a	 positive	control.	On	screening	plate	08	from	spectrum	library	and	using	the	integrated	density	as	a	measure	of	GFP	fluorescence	 I	noted	there	were	possible	hits	 in	wells	A03,	C03	D05	and	H09		
Figure	3.27	Revalidating	positive	and	negative	controls.	Representative	images	of	2dpf	embryos	from	three	groups	Top	panel	:	Tnnt2morphants,	Middle	panel:	Treatment	A	,	Bottom	panel:	Treatment	B.		
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Figure	3.28	Representative	images	of	Mid-throughput	screen	of	
Spectrum	100122	plate	8	candidates.		Top	panel:	(Right	image	is	showing	a	positive	control		(lovastatin	treated).	Left	image	represents	negative		(DMSO	treated)	controls.		Bottom	panel	represents	possible	hits	from	the	screen.	
Figure	3.29	Possible	hits	from	the	drug	screen.	Column	graph	showing	integrated	intensity	of		DMSO	treated	negative	controls	(first	column)	Lovastatin	treated	positive	controls	(second	column)	and		integrated	intensities	of	wells	(alpha-numeric)	that	could	be	possible	“	hits”	in	the	screen.		
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On	 decoding	 the	 spectrum	 library	 the	 drugs	 	 that	 came	 up	 as	 possible	 hits	 were	warfarin,	 vitamin	K	 antagonist	 (C03),	 	 fenoterol	 hydrobromide,	 a	 	 beta	 agonist	 (H09),	mebeverine	 hydrochloride,	 anticholinergic	 (H11).,	 triamicilone	 acetonide,	 a	 synthetic	corticosteroid	(A03)	and	yohimibine	hydrochloride,	an	alpha	blocker	(D05).	Triamcinolone	is	a	potent	topical	steroid	preparation.	It	is	possible	that	increased	GFP	expression	could	be	due	to	its	strong	anti-inflammatory	effects	resulting	in	suppression	of	IL1	and	TNFα.		Yohimibime	 is	 extracted	 from	 tree	 bark	 of	 yohimbe	 tree	 found	 in	west	 Africa	 .	 It	 has	vasoactive	properties	because	of	its	alpha	adrenergic	blocking	activities.	I	may	postulate	that	 yohimibine	 has	 upregulated	 GFP	 expression	 because	 of	 altering	 mechano-transductory	signals	in	developing	blood	vessels.				Both	the	above	postulates	need	to	be	 further	explored.	On	 looking	up	the	 literature	 to	find	any	reported	associations	between	any	of	the	above	drugs	I	was	not	able	to	find	any	publications	substantiating	my	postulation.												
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Discussion	Klf2	 expression	 is	 dependent	 on	 blood	 flow	 in	 the	 developing	 vasculature.	 	 In	 my	experiments	I	measured	the	intensity	of	a	GFP	signal	as	a	surrogate	for	kfl2a	expression.	Novel	orientation	tools	for	zebrafish	embryo	imaging	have	been	described	but	this	did	not	work	well	in	the	context	of	developing	a	mid	to	high	throughput	screen.		I	resorted	to	 a	 much	 quicker	 way	 of	 loading	 embryos	 into	 a	 96	 well	 plate	 for	 imaging	 by	 just	pipetting	embryos	in	clear	E3	medium	and	imaging	them.	By	dividing	each	well	into	four	quadrants	the	chances	of	capturing	fluorescence	from	all	three	embryos	was	increased.	But	 I	 found	 that	 embryos	 adjacent	 to	 the	 wall	 were	 not	 captured.	 To	 overcome	 this	problem	I	 first	 tried	to	vigorously	shake	the	96	well	plate	to	move	the	embryos	to	the	middle	 of	 the	 well.	 This	 did	 not	 work	 either.	 Hence,	 I	 used	 a	 hair	 tool	 to	 prod	 the	embryos	 as	 much	 to	 the	 middle	 of	 the	 well	 so	 as	 to	 capture	 all	 three	 embryos	 for	imaging	and	subsequent	analysis.		Whilst	 performing	 dose	 response	 analysis	 to	 find	 the	 optimal	 lovastatin	 dose,	 1dpf		zebrafish	embryos	when	 treated	with	varied	concentrations	of	 lovastatin	 for	15	hours	showed	 significant	 increase	 in	 GFP	 fluorescence,	 a	 surrogate	 for	 kf2a	 expression.	 On	performing	 a	 dose	 response	 analysis	 the	 relation	 was	 not	 linear	 and	 I	 found	 a	 4µM	concentration	 of	 lovastatin	 gave	 maximum	 increase	 in	 fluorescence.	 	 Not	 getting	 a	proportionally,	 increased	 response	 in	 doses	 higher	 than	 4µM	 could	 be	 attributed	 to	statin	 toxicity	 affecting	myotome	 architecture	 in	 embryos.	 	 Campos	 et	 al	 have	 shown	that,	zebrafish	embryos,	when	treated	with	higher	concentrations	of	simvastatin	showed	morphological	 alterations.	 These	 alterations	 in	 development	 included	 embryo	 size,	somite	size	and	shape	of	the	septa	between	the	myotomes.	There	was	also	a	reduction	in	total	cell	number	in	developing	zebrafish	embryos.	(Campos	et	al.,	2016)	
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I	 also	 found	 that	 embryos	 treated	 with	 tricaine	 and	 lovastatin	 showed	 more	 GFP	fluorescence	 than	 the	 embryos	 that	 were	 treated	 with	 tricaine	 alone	 or	 tnnt2	morphants.	The	increase	was	not	statistically	significant.	This	increase	could	be	due	to	non	flow	dependent	pathways	involved	in	klf2a	expression.	Zebrafish	embryos	showed	a	lot	of	autofluorescence	when	imaged	for	GFP	signal.	 	This	was	particularly	so	in	the	area	of	yolk	sac.	Background	fluorescence	can	also	add	to	the	values	obtained.	To	prevent	this	error	I	selected	a	finite	rectangular	area	over	the	body	of	 the	 embryos	 and	 excluded	 the	 yolk	 sac	 area.	 Further	 background	 fluorescence	was	calculated	by	drawing	a	similar	rectangle	over	the	image	that	did	not	contain	any	parts	of	 embryo.	 Corrected	 total	 fluorescence	 was	 calculated	 to	 achieve	 a	 more	 accurate	measure	of	fluorescence.	Similarly	algorithms	 that	were	designed	 for	plate-reader,	used	subtraction	methods	 to	exclude	yolk	sac	and	measured	GFP	signal,	mostly	in	vasculature	of	2dpf	embryo.		Line	graphs	were	used	to	include	lowest	and	highest	gray	scale	values	to	set	the	parameters	for	measuring	GFP	signal.			Like	 any	 other	 living	 organisms	 zebrafish	 embryos	 grow	 at	 different	 rates.	 This	 can	confound	 the	 results	 simply	 because	 of	 less	 GFP	 positive	 cells	 rather	 than	 lower	 GFP	expression.	Statistical	methods	have	been	applied	to	compute	“z	“	values	that	 factor	 in	this	variability	in	controls	and	then	applied	to	treatments	groups.			What	I	have	done	is	very	basic	development	of	this	assay	and	tried	to	be	as	meticulous	as	possible.	Having	established	the	feasibility	of	this	assay	on	a	high-throughput	plate-reader	this	can	be	further	developed	into	a	high-throughput	assay.					
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	Limitations	in	my	experimentation	were	as	follows:	
• Lots	of	human	handling	was	 required	which	 could	 subject	 this	 assay	 to	human	error.	This	can	range	from	handling	the	delicate	embryos	to	mixing	treatments.			Using	robotic	systems	can	get	rid	of	the	human	error.	
• As	 evident	 from	 the	methods	 that	 I	 adopted,	 these	 were	 time	 consuming,	 and	therefore,	decreased	the	efficiency	of	the	assay.	
• The	double	transgenics	we	used	were	out-crossed	with	fish	of	the	nacre	line.	We	did	not	use	any	phenylthiourea	(PTU)	to	prevent	melanin	production	in	embryos.	The	 reason	was	 to	 prevent	 any	 interaction	 between	 the	 drugs	 and	PTU.	Hence	there	 is	 a	 possibility	 that	 some	 of	 the	 fluorescence	was	masked	 by	 developing	melanin	pigment.	We	used	one	well	per	treatment	making	sample	size	small.	So	masking	 of	 fluorescence	 can	 have	 significant	 effect	 on	 fluorescence	quantification.	
• Linear	DNA	based	and	Tol2-mediated	transgenesis	was	used	in	the	generation	of	the	double	transgenic	zebrafish	(klf2a:GFP;kdrl:RFP)	used	in	this	assay.	However,	the	 integration	 of	 multiple	 copies	 of	 transgenes	 at	 random	 genomic	 locations	makes	long	term	transgene	stability	unpredictable	with	variable	expression.	The	variability	 in	 GFP	 expression	 in	 individual	 zebrafish	 embryos	 in	 the	 treatment	and	control	groups	can	also	be	attributed	to	the	fact	that	our	transgenic	zebrafish	line	was	not	single	copy	for	GFP	expression.	To	overcome	this	limitation	in	future	I	screened	our	klf2a:GFP;kdrl:GFP	double	transgenic	zebrafish	embryos	for	single	copy	 GFP	 expression.	 Since	 I	 out-crossed	 the	 klf2a:GFP;kdrl:GFP	 transgenic	zebrafish	with	 the	 fish	of	nacre	 line	we	expect	 some	of	 the	offsprings	will	have	lost	the	pigment.	 	Keeping	this	in	mind,	we	have	raised	60-70	fish	to	adulthood.	The	aim	of	this	exercise	is	to	establish	a	transgenic	nacre	line	that	will	be	single	
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copy	 for	 GFP	with	 nacre	 features.	 This	may	 bring	 about	 uniformity	 in	 the	 GFP	expression	and	better	capture	of	GFP	fluorescence	in	future	experiments.	
• Another	aspect	of	this	assay	that	can	be	further	developed	is	imaging.	Using	a	2X	objective	does	not	give	enough	resolution	to	detail	the	structure	of	2dpf	embryos.	This	 results	 in	 GFP	 expressing	 cells	 group	 together	 as	 a	 blob	 rather	 than	 a	discrete	 dot.	 This	 can	 affect	 the	 fluorescence	 calculated	 by	 segmentation	methods.	 In	 future	 it	may	 be	 useful	 to	 try	 using	 a	 10x	 or	 a	 20X	 objectives	 for	better	resolution	and	more	accurate	fluorescence	quantification.	
Future	Directions	Zebrafish	 embryos	 are	 going	 to	 be	 used	 more	 and	 more	 in	 future	 for	 initial	 drug	screening.	This	assay	model	can	help	in	finding	drugs	that	will	enhance	GFP	fluorescence	a	 surrogate	 for	 klf2a	 expression.	 	 Klf2	 is	 an	 atheroprotective	 gene	 and	 its	 increased	expression	 can	 prevent	 progression	 of	 atherosclerosis.	 	 The	 advantage	 of	 screening	already	licensed	drugs	for	upregulatory	effect	on	klf2a	expression	is	that	the	possible	hit	can	be	fast	tracked	into	a	therapeutic	option.		During	embryonic	development	klf2a	is	expressed	in	pectoral	fins	and	squamous	cells	in	epidermis.	So	further	drug	screens	can	be	developed	which	are	relevant	to	skin	and	limb	development.	In	view	of	the	sequence	divergence	between	zebrafish	and	human	receptor	proteins	one	would	 expect	 a	modest	 conservation	 of	 pharmacological	 effects.	 	 Actually	 the	 rates	 of	conservation	are	high	mostly	due	to	high	target	similarity	at	active	sites.		82%	of	disease	causing	human	proteins	have	an	orthologue	in	zebrafish	(Howe	et	al.,	2013).	Due	to	the	ease	with	which	zebrafish	can	be	genetically	modified	zebrafish	screening	will	become	more	and	more	relevant		in	drug	screening	and	developing	treatment	strategies.		
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Automation	 leading	 to	use	 of	 robots	 for	 zebrafish	 embryo	handling	 and	drug	delivery	are	 finding	 increasing	 use	 in	 drug	 screening	 thus	making	 drug	 screens	more	 efficient	and	precise.		Fecundity	of	zebrafish	can	be	manipulated	to	produce	more	eggs.	This	can	result	 in	 large	 drug	 screens	 involving	 thousands	 of	 drugs.	 (Rennekamp	 and	 Peterson,	2015).			Using	 TALENs	 and	 CRISPR-Cas	 technologies	 it	 has	 been	 possible	 to	 create	 human	disease	in	zebrafish.(Xiao	et	al.,	2013)	(Irion	et	al.,	2014).	Geneticists	have	discovered	thousands	 of	 mutations	 associated	 with	 human	 disease.	 	 Successful	 teaming	 of	zebrafish	 and	 traditional	 drug	 development	 approaches	 will	 help	 in	 developing	individualized	therapeutics.		Though	the	role	of	zebrafish	in	drug	screening	is	on	an	increase,	there	are	significant	challenges	that	need	to	be	overcome.		Controlling	and	quantifying	drug	exposure	is	one	of	 them.	 It	 is	 easy	 to	 determine	 the	 concentration	 of	 drug	 in	 plate	 water,	 but	quantifying	drug	concentrations	in	microscopic	larvae	is	very	difficult.	This	can	result	in	 false	 negatives,	 where	 a	 drug	 cannot	 show	 its	 efficacy	 for	 lack	 of	 absorption	 by	zebrafish	 embryos.	 False	 negatives	 will	 negatively	 affect	 a	 toxicity	 screen	 as,	 toxic	compounds	may	not	be	identified	for	lack	of	absorption.	As	 	more	experience	is	gathered	assays	will	become	more	standardized	and	will	bear	better	formal	relationship	with	other	pre-clinical	models.	Also	toxicity	or	efficacy	of	a	drug	will	have	to	be	measured	in	a	standard	fashion,	which	can	then	help	in	comparing	the	results.		Zebrafish	 drug	 screening	 in	 my	 opinion	 will	 be	 an	 important	 tool	 in	 developing	individualized	therapeutics.		
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I	 would	 like	 to	 conclude	 by	 stating	 that	 the	 drug-screening	 assay	 I	 developed	 can	 be	used	 for	 initial	 whole	 organism	 drug	 screening.	 This	 assay	 will	 be	 able	 to	 find	 hits	resulting	 in	 increased	 GFP	 expression.	 Once	 hits	 are	 established	 they	will	 need	 to	 be	further	tested	by	molecular	biology	methods	to	prove	that	increased	GFP	fluorescence	is	definitely	a	surrogate	of	klf2a	upregulation.				 			
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